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Résumé 
Les sites apuriniques/apyrimidiniques (AP) sont des sites de l’ADN hautement mutagène. 
Les dommages au niveau de ces sites peuvent survenir spontanément ou être induits par 
une variété d’agents. Chez l’humain, les sites AP sont réparés principalement par APE1, 
une enzyme de réparation de l’ADN qui fait partie de la voie de réparation par excision 
de base (BER). APE1 est une enzyme multifonctionnelle; c’est une AP endonucléase, 3’-
diestérase et un facteur redox impliqué dans l’activation des facteurs de transcription. 
Récemment, il a été démontré qu’APE1 interagit avec l’enzyme glycolytique GAPDH. 
Cette interaction induit l’activation d’APE1 par réduction. En outre, la délétion du gène 
GAPDH sensibilise les cellules aux agents endommageant l’ADN, induit une 
augmentation de formation spontanée des sites AP et réduit la prolifération cellulaire. A 
partir de toutes ces données, il était donc intéressant d’étudier l’effet de la délétion de 
GAPDH sur la progression du cycle cellulaire, sur la distribution cellulaire d’APE1 et 
d’identifier la cystéine(s) d’APE1 cible(s) de la réduction par GAPDH. Nos travaux de 
recherche ont montré que la déficience en GAPDH cause un arrêt du cycle cellulaire en 
phase G1. Cet arrêt est probablement dû à l’accumulation des dommages engendrant un 
retard au cours duquel la cellule pourra réparer son ADN. De plus, nous avons observé 
des foci nucléaires dans les cellules déficientes en GAPDH qui peuvent représenter des 
agrégats d’APE1 sous sa forme oxydée ou bien des focis de la protéine inactive au niveau 
des lésions d’ADN. Nous avons utilisé la mutagénèse dirigée pour créer des mutants (Cys 
en Ala) des sept cystéines d’APE1 qui ont été cloné dans un vecteur d’expression dans 
les cellules de  mammifères. Nous émettons l’hypothèse qu’au moins un mutant ou plus 
va être résistant à l’inactivation par oxydation puisque l’alanine ne peut pas s’engager 
dans la formation des ponts disulfures. Par conséquent, on anticipe que l’expression de ce 
mutant dans les cellules déficientes en GAPDH pourrait restaurer une distribution 
cellulaire normale de APE1, libérerait les cellules de l’arrêt en phase G1 et diminuerait la 
sensibilité aux agents endommageant l’ADN. En conclusion, il semble que GAPDH, en 
préservant l’activité d’APE1, joue un nouveau rôle pour maintenir l’intégrité génomique 
des cellules aussi bien dans les conditions normales qu’en réponse au stress oxydatif.                                     
Mots clés : APE1, GAPDH, délétion de GAPDH,  dommage à l’ADN, cysteine, site AP. 
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Abstract 
Apurinic/apyrimidinic (AP) sites are highly mutagenic DNA lesions occurring either 
spontaneously or by the action of DNA damaging agents. In human cells, AP sites are 
processed by the major DNA repair enzyme APE1 through the base excision repair 
(BER) pathway. APE1 is a multifunctional protein that has AP endonuclease/3’-
diesterase activities in addition to its role as a redox factor in activating many 
transcription factor. Recently, it has been shown that APE1 interacts with the glycolytic 
enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH), an interaction that results 
in the activation of APE1 by reduction. Interestingly, depletion of GAPDH sensitized the 
cells to DNA damaging agents and induced an increase in spontaneous AP sites 
frequency. Moreover, cells knocked-down for GAPDH showed defects in proliferation. 
Here we set up to investigate the effects of GAPDH knockdown on cell cycle 
progression, APE1 subcellular localization and to identify the cysteine residue(s) of 
APE1, target(s) of GAPDH reduction. Our studies showed that GAPDH deficient cells 
arrested in G1 phase of the cell cycle. The defect in cell cycle progression is most 
probably due to accumulation of DNA damage which activates checkpoints leading to a 
delay in the cell cycle to allow DNA repair. Furthermore, in GAPDH deficient cells, 
APE1 formed nuclear foci-like structures that could represent aggregates of the oxidized 
form of APE1 or inactive APE1 foci on DNA lesions. Using site-directed mutagenesis, 
we created seven APE1 cysteine to alanine mutants which were cloned into a mammalian 
expression vector. We expect that at least one of these mutants is likely to resist the 
inactivation by oxidation as it cannot engage in disulfide bridge formation. Therefore, the 
expression of this mutant(s) in GAPDH knockdown cells is expected to restore a normal 
APE1 cellular distribution, rescue the cell cycle defects, and render the cells less sensitive 
to DNA damaging agents. In conclusion, our results show a new role of GAPDH in 
maintaining genomic stability under oxidative stress by maintaining APE1 in its 
functional state. 
 
Key words:  APE1, GAPDH, GAPDH knockdown, DNA damage, cysteine, AP sites. 
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Chapter 1: Introduction 
1. General Overview 
140 years after  its discovery,  deoxyribonucleic acid (DNA), the genetic material and the 
blueprint of the cell, is known to be responsible for holding the information needed to 
constitute all the components of a living cell, hence of a whole organism. Today, we are 
still studying its structure, its transmission from one generation to the other, its 
interaction with its environment and its regulation by different known and unknown 
factors in a cell’s micro- and macro-environment.  
The cell faces many challanges throughout its life, leaving it with different kinds of 
damaging agents that cause damage to proteins (enzymes, structural proteins, etc...), to 
DNA and to other important components. The cellular response to damage depends on 
the cell type and the nature of damage. It either resolves the problem or bypasses it, 
leaving in the latter case a potential permanent damage [1]. As one would expect, damage 
to DNA is the most harmful damage that a cell might undergo due to many facts. First, 
DNA replication will allow this damage, or “mutation” in other terms, to be transmitted 
to daughter cells; second, DNA transcription will give a modified protein product that 
might be non-functional. In fact, damage to DNA is considered to be the early step to 
carcinogenesis, mutagenesis, and aging [2, 3]. Consequently, the cell has evolved DNA 
repair pathways to overcome these challenges, as one of its surviving tools. 
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2. DNA Damage 
Genome integrity is continuously challenged by endogenous and exogenous agents, 
which might generate different unwanted insults. Identifying the sources and nature of 
these insults is of crucial importance for the cell to determine the damage-specific 
strategy in order to remove a given lesion. 
 
2.1 Sources of DNA damage 
2.1.1 Endogenous origin 
While the cell struggles to protect its genome from different damaging agents, it 
produces, ironically, its own “homemade” DNA damaging products, mainly reactive 
oxygen species (ROS) and reactive nitrogen species (RNS).  
ROS are oxygen-derived free radicals that have one or more unpaired electrons. 
Superoxide (O2−), Hydrogen peroxide (H2O2) (non radical), hydroxyl radical (OH·) 
among others belong to ROS family. On the other hand, RNS are nitrogenous products of 
nitric oxide synthases, ranging from Nitric Oxide to Nitrates [4]. ROS and RNS are 
produced by cellular metabolisms as by-products of the mitochondrial electron transport 
reactions and some metal-catalyzed reactions. They are also produced by immune system 
cells like neutrophils and macrophages during inflammation. Moreover, their formation 
can be induced by external factors like ultra-violet (UV) light, gamma radiation and X-
rays. ROS can exist as pollutants in the atmosphere as well [5].  Once in the cell, these 
species may  damage proteins, lipids and nucleic acids [6]. The harmful effects of ROS 
3 
can be balanced by an antioxidant system which includes enzymatic (e.g. superoxide 
dismutase SOD) and non-enzymatic antioxidants (e.g. vitamin E). Oxidative stress occurs 
when the balance between antioxidant and ROS production favours the latter. In DNA, 
ROS primarily induces oxidized bases and single-strand breaks (See section 2.2 for 
details). Paradoxically, at low concentrations, ROS and RNS can benefit the cell by 
increasing defence against infectious agents [6].  
In addition to ROS, some naturally occurring phenomena, such as meiosis, V(D)J and 
class switch recombination in immunoglobulin rearrangements may also cause damage to 
DNA [7].  
 
2.1.2 Exogenous Sources  
Besides endogenous sources of DNA damage, the cell is subject to many exogenous 
factors that are either naturally occurring in a given cellular environment, like viral 
infection, UV-light from the sun and ionizing radiations (e.g. gamma radiation, X-rays...), 
or that are human-made like many mutagenic/carcinogenic substances (e.g. tobacco, 
DNA intercalating agents like ethidium bromide, etc...). These factors might act directly 
on DNA or indirectly by inducing an increase in ROS levels which, subsequently will 
damage the DNA. Chemotherapeutic drugs targeting the DNA are another example of 
man-made damaging agents [6]. They are divided into many categories: alkylating 
agents, antimetabolites, anthracyclines, plant alkaloids and topoisomerase inhibitors. All 
of these drugs lead to accumulated damage on the DNA which might interfere with 
cancer cell division and survival. Many secondary effects were associated with this type 
4 
of cancer treatment and the main reason is the untargeted mode of action of many of 
these drugs and their impact on healthy cells [8]. 
 
2.2 Types of DNA damage 
DNA damage refers to any structural alteration of the DNA that will interfere with its 
normal conformation and composition leading to errors in transcription and replication. 
The types of DNA lesions vary depending on the origin of the damage and the targeted 
part of the DNA. DNA damaging agents can affect the nitrogenous bases as well as the 
sugar backbone. Base damage includes: oxidation, alkylation and deamination. Bases can 
also be spontaneously lost by hydrolysis. The DNA backbone can be broken on one or 
both strands leading to single strand breaks (SSBs) and double strand breaks (DSBs) [9]. 
 
2.2.1 Spontaneous base loss and AP sites 
The N-glycosidic bonds that hold the nitrogenous bases to the sugar-phosphate backbone 
are weak points in the structure of DNA. Hydrolysis of this bond by a water molecule 
leads to the loss of the base and creating an apurinic-apyrimidinic (AP) site, also known 
as abasic site (figure1) [10]. The double ring structure of purines, adenine (A) and 
guanine (G), makes them more susceptible for hydrolysis than pyrimidines [10, 11].  AP 
sites are highly mutagenic lesions that interfere with DNA transcription and replication 
by blocking DNA and RNA polymerases. Some DNA polymerases bypass AP sites, 
incorporating an untemplated nucleotide into the newly synthesized strand, introducing 
5 
mutations [12, 13]. AP sites can also be generated as intermediates in the repair of base 
lesions by the base excision repair (BER) pathway, the main DNA repair pathways that 
repairs AP sites. (See section 4.1.1).  
 
Figure 1. Abasic site. Adapted from [14]. 
  
2.2.2 Base modification 
2.2.2.1 Base oxidation 
DNA bases are subject to oxidation by different radicals, the most prominent of which is 
hydroxyl radical (OH·). Oxidation usually occurs on carbons 5 and 6 of pyrimidines and 
carbons 4 and 8 of purines [15]. Bases can be oxidized either within the DNA strand or in 
the dNTP pool before incorporation [16]. Some common oxidized bases include                               
8-oxoguanine (8-oxo-G), thymine glycol, uracil glycol, FapyG, and 5-formyluracil 
(figure 2). High levels of 8-oxo-G and thymine glycol have been reported under normal 
conditions as well as under oxidative stress in both nuclear and mitochondrial DNA [17]. 
They are highly mutagenic, if left unrepaired, they will lead to mutations that are lethal in 
some cases. The DNA polymerase might bypass this type of lesions, inserting the wrong 
nucleotide, thus creating transversion mutations as a consequence. Moreover, they can 
6 
lead to replication fork arrest after blocking the DNA polymerase, which might induce 
checkpoint responses and apoptosis. Modified bases can be removed by DNA 
glycosylases which cleave the N-glycosylic bond between the sugar and the base, leaving 
behind an AP site [16]. It is noteworthy that the sugar moiety of the DNA might undergo 
oxidation as well. In this latter case, oxidized AP sites and SSBs with 3’ blocking groups 
are the possible outcomes [18] (see section 2.2.4).  
 
Figure 2. Examples of Oxidized bases. 
2.2.2.2 Base alkylation 
The transfer of an alkyl group to a nitrogenous base is another common base modification 
[19]. S-adenosylmethionine (SAM) is a well-characterized endogenous source of 
methylated bases, as it has a reactive methyl group that can be transferred to a DNA base, 
giving rise to 7-methylguanine (7-MeG) or 3-methyladenine (3-MeA) (figure 3) [20]. 
The drug methyl methanesulfonate (MMS) also induces these lesions [21]. 3-MeA blocks 
RNA and DNA polymerases and is highly toxic intermediates, whereas 7-MeG seems 
harmless. Alkyladenine-DNA glycosylase (AAG) is the only human enzyme that excises 
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3MeA from DNA, and creates AP sites as a consequence [22]. 
 
Figure 3. Examples of alkylated bases 
2.2.2.3 Base deamination 
Base deamination is the removal of the amine group, usually by hydrolysis, from DNA 
nucleobases. Hydrolytic deamination of cytosine generates uracil, which leads to GC to 
AT transversion mutations after DNA replication. Uracil-DNA glycosylase (UDG) 
hydrolyses the glycosylic bond between the uracil and the sugar, creating an AP site.                                      
5-Methylcytosine can undergo a spontaneous deamination, generating thymine. 
Consequently, C to T transversions are the most common single point mutations. Such 
mutations are particularly dangerous because the thymine is not recognized as a damaged 
base [23]. Mismatch repair pathway allows the recognition and repair of mismatched 
bases as well as some insertions and deletions that occur during DNA replication or 
recombination [24].  Another way to deaminate DNA bases is by the action of reactive 
nitrogen species (RNS) in addition to several proteins such as activation-induced cytidine 
deaminase (AID) and Apolipoprotein B mRNA editing catalytic subunit 1 
(APOBEC1)[25, 26]. 
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2.2.3 Bulky lesions and cross links 
Bulky lesions and inter- or intra-strand cross links are caused by the UV-light. The main 
lesions created by UVB are cis-syn cyclobutane pyrimidine dimers (CPDs) and 
pyrimidine (6-4) – pyrimidone photoproducts (figure 4), which connect adjacent 
pyrimidine molecules present in the same or different strands of the DNA to create a 
distortion in the DNA structure . 4-Nitroquinoline 1-oxide (4NQO) is a UV-mimetic drug 
that causes the above mentioned DNA lesions that are repaired by the nucleotide excision 
repair (NER) pathway. Deficiency in repairing such lesions has been associated with 
important human DNA repair syndromes such as xeroderma pigmentosum (XP) and 
Cockayne syndrome (CS) [27]. 
 
Figure 4. Main DNA lesions induced by UV-light. 
 
2.2.4 Sugar-phosphate backbone breakage 
2.2.4.1 Single strand breaks 
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SSBs are discontinuities in one strand of the DNA duplex. They occur as a result of 
spontaneous hydrolysis of the sugar-phosphate backbone, as a consequence of ionizing 
radiation (IR), or elevated ROS levels. SSBs can form directly by the removal of the 
oxidized sugar or indirectly during the base-excision repair (BER) of damaged bases. In 
the latter case, a DNA glycosylase cleaves off the damaged base to create an AP sites 
which is then cleaved by an AP endonuclease or lyase to create a SSB [28-30]. In 
addition to the sources mentioned above, some chemotherapeutic drugs directly induce 
SSBs. For example, bleomycin creates SSBs with 5’-phosphate and 3’-phosphoglycolate 
or 3’-phosphate termini [31].  
If not repaired rapidly or appropriately, SSBs create a serious threat to chromosomal 
stability and hence cell survival. Consequently, cells have evolved rapid and efficient 
mechanisms for their repair during later stages of the BER pathway for instance [32]. 
(See section 4.1.1 for more details). 
 
2.2.4.2 Double strand breaks 
DSBs are the most dangerous DNA lesions because they can lead to large-scale genomic 
rearrangement and chromosomal fusions (translocations, deletions). A lot of naturally 
occurring phenomena prompt the formation of DSBs like: meiosis, mating type switching 
(in yeast), V(D)J and immunoglobulin class switch recombination. External factors like 
IR, drugs like bleomycin and chemicals also contribute to the formation of DNA DSBs. 
They are repaired mainly by two pathways: Homologous recombination (HR) and Non-
homologous end joining (NHEJ) [7, 33-35].  
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3. DNA Damage response 
Cells have developed elaborate mechanisms to sense and respond to DNA damage. These 
mechanisms are collectively called DNA damage response (DDR). DDR is today known 
to be a signal transduction pathway as it appeared to be a kinase cascade activated by 
DNA damage and replication stress. The main kinases of this pathways are ataxia 
telangiectasia and Rad3-related (ATR) and Ataxia telangiectasia mutated (ATM), a 
defect in which was associated with ataxia telangiectasia (AT) disease[36]. Although it 
was thought for years that the purpose of this cascade is to regulate the cell cycle 
transition, in the last decade it was shown that the DDR is versatile and that cell cycle 
control, at checkpoints level, is only one of many outcomes controlled by this sensory 
network whose central goal is the repair of DNA [37].  
In human cells, DNA damage activates p53 which then  induces the transcription of p21, 
a major inhibitor of the Cyclin-dependent kinases (CdKs). The inhibition of CdKs 
induces cell cycle arrest [38]. Moreover, Chk1 and Chk2, the two serine/threonine 
kinases that act downstream of ATR/ATM, are activated by phosphorylation in response 
to DNA damage. The activation of Chk1 and Chk2 leads to the inhibition of Cdc25, a 
dual specificity phosphatase that ensures cell cycle progression by promoting phase 
transition [39, 40]. Chk1 is the primary effector of the intra-S and G2/M phase 
checkpoints, whereas Chk2 plays a minor role on the intra-S and G1/S checkpoints [41]. 
Figure 5 represents a simplified scheme of the cell cycle checkpoint pathways and the 
main key proteins involved and their effect on the cell cycle progression. 
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Figure 5.  Cell cycle checkpoint pathways induced in response to DNA 
damage. In red: Tumor suppressors ; in green: proto-oncogenes. Adapted from 
[42]. 
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4. DNA repair: a crucial line of defence 
4.1 DNA repair pathways 
The diversity and specificity of DNA repair pathways come from the need to repair 
different types of lesions that arise in the DNA. DNA repair pathways are damage- 
specific as shown in figure 6 that summarizes different types of damages, types of 
lesions created and the major DNA repair pathway involved. 
4.1.1 Base excision repair  
This section will summarize BER in more details, focusing mainly on the pathway as it 
occurs in humans. 
Base excision repair (BER) is a vital DNA repair pathway for living cells since it is 
responsible for correcting most common types of damages occurring in the genome: 
damaged bases (e.g. deaminated, oxidized and alkylated bases), AP sites, as well as 
single strand breaks with 3’-blocked termini [43, 44]. Given this role, BER pathway is 
considered one of the major DNA repair pathways that deals with most DNA damage 
[45, 46]. Moreover, this pathway is well conserved from bacteria to human in terms of 
the core components of its DNA repair machinery [47, 48].   
The BER pathway was discovered nearly 35 years ago by Thomas Lindahl who searched 
for an enzymatic activity that catalyzed the removal of uracil from DNA. In E.coli, he 
identified uracil DNA glycosylase (UDG) [49, 50], and other groups subsequently 
demonstrated that this enzyme is conserved in most organisms [51, 52]. 
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Figure 6. The main damage-specific DNA repair pathways in human cells. DNA-damaging agents 
(top), examples of DNA lesions (middle), and the Corresponding DNA repair pathways (bottom). The 
essential genes involved in each DNA repair pathway are shown below the corresponding titles. HR, 
homologous recombination; NHEJ non-homologous end-joining. Adapted from [53], [54] and [55]. 
                                                                                                                                                                              
Subsequent work over the next two decades identified more glycosylases specific for 
other damaged bases as well as AP endonucleases [56, 57].   
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BER occurs in five major steps: (1) Recognition and removal of the damaged base, (2) 
enzymatic incision of the AP site, (3) processing of the ends of the SSB by AP site 
incision, (4) repair DNA synthesis, and finally (5) ligation of nick to restore the 
continuity of the DNA strand [58]. These will be discussed in detail below, with an 
emphasis on step 2. Figure 7 represents an overview of the pathway. 
 
Figure 7. Overview of the BER pathway and its subpathways. Adapted from [47] 
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4.1.1.1 Damage Recognition 
The first step in BER is the recognition of the modified base by a DNA glycosylase. 
Glycosylases cleave the N-glycosylic bond linking the damaged base to its corresponding 
deoxyribose sugar. DNA glycosylases are classified as either mono or bi-functional. 
While both classes of glycosylases hydrolyze the N-glycosylic bond, bifunctional 
glycosylases, such as 8-oxoguanine glycosylase (OGG1) and NEIL1/2/3, are endowed 
with an additional AP lyase activity. These enzymes can further process the AP site 
through β or β-δ-elimination to generate SSB with 3’-polyunsaturated aldehyde or 3’-
phosphate termini, respectively [59-61]. Although DNA glycosylases are substrate 
specific, the recognition of different modified bases by the same glycosylase, or the same 
damaged base by multiple glycosylases still occur, thus providing redundancy [62].  
 
4.1.1.2 AP sites and blocking groups processing 
The removal of the modified base by the DNA glycosylase generates the highly 
mutagenic AP site intermediate. These lesions are substrates of the catalytic activity of 
AP endonuclease family, AP lyases and delta lyases. While delta lyases create an incision 
at AP sites and process 3’-aldehyde to create 3’-phosphate termini, AP endonuclease 
enzymes incise the phosphodiester backbone at the 5’side of AP sites to generate 3’-
hydroxyl and 5’-deoxyribosephosphate (dRP) termini [61]. These unconventional termini 
have to be restored to 3’-OH and 5’-P through deoxyribose-phosphatase diesterase 
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(dRPase) activity of Pol β (5’-dRP), 3’ diesterase activity of the Apurinic/apyrimidinic 
endonuclease 1 APE1 (3’-PUA) and the phosphatase activity of PNKP in order to allow 
further repair [14, 58].  
However, between the AP endonucleases and the AP lyases cleavage of AP sites, the AP 
endonuclease incision is the predominant pathway [61]. The importance of AP 
endonucleases functions over the AP lyases has also been supported by findings   
showing that endonuclease deficient yeast strains are more sensitive to MMS, but not AP 
lyase deficient yeast strains [63, 64]. AP endonuclease families will be discussed in 
further details in sections 5.  
 
4.1.1.3 BER sub-pathways: the short and long patch 
4.1.1.3.1 Short Patch BER 
In SP-BER, DNA polymerase β (POL β) performs a one-nucleotide gap-filling reaction 
and removes the 5’dRP via its lyase activity. This is then followed by sealing of the 
remaining nick by the XRCC1–ligase3 complex. XRCC1 is a scaffold protein that 
interacts with several of  the BER core components and may therefore be important in 
protein exchange [65]. 
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4.1.1.3.2 Long Patch BER 
In long-patch BER (LP-BER), APE1 catalyzes the formation of a nick 5’ to the AP site. 
This action recruits POL β or DNA polymerase δ (POL δ), PCNA, flap structure-specific 
endonuclease 1 (FEN1), and DNA ligase 1 (LIG1). In a PCNA-dependent manner POL β 
performs displacing synthesis and polymerizes a tract of DNA from ~2-10 bases, which 
produces a flapped substrate that is refractory to ligation. FEN1 cleaves the flap at the 
ssDNA-dsDNA junction, creating a ligatable nick, which is then sealed by DNA ligase I 
[66].  
It was concluded that the short-patch BER (SP-BER) repair is probably the dominant 
subpathway of BER. [53]. However, it was shown that many factors  such as cell state 
(cell cycle phase, differentiation stage), BER protein–protein interactions and the types of 
lesions are all involved in the selection between SP- and LP-BER [67]. 
 
4.1.1.4 BER and cancer 
Cancer is, without any doubt, the disease of the past century. Since AP sites are 
considered the most occurring type of lesions arising in the DNA, they are major 
contributors to DNA mutations. Accumulated mutations often lead to subsequent 
activation of proto-oncogenes and inactivation of tumour-suppressor genes, the hallmarks 
of cancer. Therefore, BER implication as a cancer-prevention pathway is essential.  
Indeed, numerous links have been identified between oncogenesis and acquired or 
inherited alterations in the genome “guardians”, highlighting the key role of DNA repair 
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systems in tumour prevention. In the last decade, evidence of association of BER 
deficiency with cancer has started to emerge. For instance, studies have demonstrated a 
link between defects in the adenine–DNA glycosylase MYH and adenomatous colorectal 
polyposis and colorectal cancer risk [68]. Reduced activity of OGG1 was associated with 
elevated lung cancer [69].                                                                                                         
Moreover, BER enzymes are attractive targets for inhibitor-based cancer therapy. Many 
chemotherapeutic drugs act by damaging the DNA, leading to cell death. Therefore, 
selective inhibition of repair in cancer cells could sensitize them to the drug [70]. 
 
5. AP Endonuclease/3’ -Diesterase 
AP sites are very common because, besides being formed spontaneously, they are 
intermediates in repair of most types of base damage. AP sites are repaired primarily by 
AP lyases and AP endonucleases. AP endonuclease family members cleave the sugar-
phosphate bond 5′ of an AP site to produce a 3′ hydroxyl group and a 5′-deoxyribose 
phosphate [71, 72]. The first evidence of the presence of an enzyme that is capable of 
processing AP sites emerged from studies in E.coli. These studies showed that an enzyme 
termed exonuclease III, first described as a 3’ to 5’ exonuclease with a 3’-phosphatase 
activity, also possesses an AP endonuclease activity [73, 74]. To date, two families of AP 
endonucleases / 3’-diesterases, named Endonuclease IV (Endo IV) and Exonuclease III 
(Exo III) after the ancestral bacterial enzymes, have been well characterized [61]. In 
addition to AP endonucleases, AP lyases are also capable of processing AP sites. In fact, 
the E. coli endonuclease III is an AP lyase that cleaves on the 3′ side of the AP site 
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through a β-elimination reaction to produce a SSB with 3’ α,β-unsaturated aldehyde, 
processed by AP endonucleases [75, 76].   
 
5.1 Two Distinct families of AP endonucleases/3’ 
Diesterase 
Despite a certain degree of redundancy between the Exo III and Endo IV AP 
endonucleases families, some differences in expression and substrate specificity do exist. 
However, the key feature used to differentiate between the two families is their 
magnesium dependency. While members of the Endo IV family are Mg2+ independent, 
Exo III family members require magnesium for their DNA repair activity [61]. 
Interestingly, these two proteins use completely different structural folds to accomplish 
basically the same set of activities [77].                                                                                                               
In E.coli, Exo III is encoded by the xth gene and is the major AP endonuclease 
accounting for around 90% of the total AP endonuclease activity in extracts. Exo III 
possesses four different catalytic activities. First, Exo III is an apurinic/apyrimidinic 
endonuclease activity. Second, it has a 3’ to 5’ exonuclease with an activity specific for 
dsDNA allowing it to degrade blunt ends and 5’ overhangs. Third, it can also act as a 3’ -
phosphodiesterase that removes groups including,  phosphates and phosphoglycolate in 
addition to the aldehydes left by AP lyases [78-80] to allow the DNA polymerase to 
prime DNA synthesis from a 3’ -OH [71]. Fourth, it has an RNase H activity to degrade 
RNA in DNA-RNA hybrids [57, 81, 82]. 
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While Exo III family members are present in all kingdoms of life, Endo IV homolog exist 
in prokaryotes and lower eukaryotes, but not in plants, mammals and many other 
vertebrates. Like Exo III family members, the Endo IV enzymes possess 3’-diesterase,                     
3’ -exonuclease and  RNase H activities [61].                                                                                                      
In E.coli Endo IV is encoded by the nfo gene. It accounts for only 10% of the basal AP 
endonuclease activity but is induced by oxidative stress [57, 82]. In contrast, Apn1, the                                  
S. cerevisiae Endo IV homolog, is the major AP endonuclease in yeast and shares 41% 
sequence identity with the bacterial enzyme [83]. Yeast apn1Δ cells show less than 1% of 
AP endonuclease/3’ diesterase activities of wild-type, a 60 fold increase in ATGC 
transversion mutations, and hypersensitivity to alkylating agents and chemical 
oxidants[84, 85]. Apn2, the E.coli Exo III homolog in yeast  was discovered as the 
second and the minor AP endonuclease in yeast after Apn1 [86]. As in E.coli, yeast Apn2 
was shown to possess AP endonuclease, 3’ diesterase and 3’ to 5’ exonuclease activities 
that require magnesium [63]. The transcription of Apn2 gene was found to be induced up 
to six-fold by treatment with  MMS [87] and its 3’-diesterase and 3’→5’ exonuclease 
activities stimulated by proliferating cell nuclear antigen (PCNA) [88].  
In human cells, AP endonuclease 1 (APE1) and AP endonuclease 2 (APE2) are the 
human homologues of the Exo III family. APE1 is the major human AP endonuclease/3’ 
diesterase and since the research project concentrates on the DNA repair capacity of 
APE1, this enzyme will be discussed in more details in section 6 below. This enzyme has 
previously been known as APEX in mice [89], “HAP1” for Human AP endonuclease 1 
[90], and redox factor-1 (Ref-1) for its role as a redox regulator [91], but will be referred 
to as APE1 here. 
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Based on genomic databases from various organisms, APE2 was identified as a nuclear 
and mitochondrial AP endonuclease in human cells[92]. APE2 was found to possess a 
very weak AP endonuclease activity and an even weaker (7-fold lower) 3’ diesterase 
activity [93]. Moreover, APE2, unlike APE1, could not complement yeast AP 
endonuclease mutants [94]. While APE1 has been reported to have no functional 
mitochondrial targeting sequence (MTS), it was shown that APE2 possesses a MTS and 
has a potential role in the repair of mitochondrial DNA lesions [92]. Moreover, it was 
reported that APE2 has a long C-terminal domain that contains a PCNA binding motif, 
similar to the one present in S. cerevisiae Apn2, suggesting a possible role in LB-BER 
[92]. However, the presence of APE2 did not rescue the lethal phenotypes of the 
knockout and the knockdown of APE1, which rule out possible significant roles for 
APE2 in DNA repair. The in vivo role of APE2 remains unclear; it might be a 
pseudogene or an evolutionary relic.    
 
Many attempts failed to identify the Endo IV homolog in human. The highest organism 
where both AP endonucleases were identified and characterized is Caenorhabditis 
elegans (C.elegans) [95, 96]. In addition, Exo III and Endo IV were both identified but 
not yet characterized in the frog Xenopus tropicalis and the fish Danio rerio [97].      
                                 
6. APE1 
APE1 was first characterized and purified from HeLa cells in  1981 by the group of 
Stuart Linn [98]. Later, cDNAs encoding several mammalian AP endonucleases (human, 
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murine and bovine) were published [99-102]. The APE1 protein is closely related to other 
mammalian AP endonucleases (91-93% identity) and more distantly to E.coli Exo III 
(28% identity). Like Exo III, APE1 has a Mg2+- dependent AP endonuclease activity in 
vitro [98, 103]. 
 
6.1 APE1: a DNA repair enzyme 
As described earlier, APE1 is considered of major importance in protecting the cell from 
the effects of cytotoxic and mutagenic unrepaired AP sites.                                                                               
The expression of the APE1 protein in human cells is activated by DNA damaging agents 
and ROS, in order to process the resulting AP sites during the BER [104]. The second 
major role of APE1 in the BER is its 3’ diesterase activity. Although the diesterase 
activity of APE1 is about 200-fold lower than its AP endonuclease activity, this function 
allows it to remove a variety of 3’ blocking groups including 3’phosphate and 3’ 
phosphoglycolate occurring at single-strand breaks created by oxidative agents, ionizing 
radiation or by a chemotherapeutic agent like Bleomycin which creates 3’ 
phosphoglycolate [105, 106].       
APE1 is one of the major enzymes orchestrating the mammalian BER. In addition to its 
AP endonuclease/3’ –diesterase activity, APE1 may have also an implication in the 
selection between the SP- and LP-BER subpathways. It was proposed that APE1 is active 
in both LP- and SP-BER and that it interacts with several proteins in these two 
subpathways including OGG1, XRCC1, PCNA, FEN1, and DNA polymerase β. Hence, 
APE1, owing to its interactions with other BER proteins and to its structural mechanism 
23 
of recognition of the AP site, it serves as an assembly and coordination factor for 
subsequent proteins after its initial cleavage of the DNA [107, 108].  
In the first step of BER, after the DNA glycosylase removes the damaged base, it remains 
bound and presents the AP site to APE1. Due to the extensive surface of APE1-DNA 
interaction that covers both DNA strands and the DNA kinking, APE1 displaces the 
glycosylase allowing it to release the damaged base. After cleaving the AP site, the 
nicked DNA is exposed to DNA polymerase and/or XRCC1. This product-substrate 
exchange might be partially mediated by APE1 N-terminal and the DNA polymerase 
dRP-diesterase domain. Following repair, the DNA can no longer accommodate the 
bending and the component enzymes likely dissociate [109]. It appears that APE1 
interactions with other BER proteins show a high level of DNA repair organization for 
maximal efficiency in a relatively large mammalian genome.  
Although they belong to different AP endonucleases families and to two different 
species, it is noteworthy that the human APE1 shares many common features with the 
yeast Apn1. First, each one of them is the major AP endonuclease/3’ diesterase enzyme 
in its corresponding cellular context. Second, they are both capable of incising the 
phosphodiester bond at the 5’ of an AP site and of removing similar 3’ blocking groups, 
e.g. 3’ phosphate, 3’phosphoglycolate that are associated with Ionizing radiation (IR) and 
ROS [71, 110, 111].  However, in contrast to what might be predicted based of the 
biochemical repair activities of APE1 and Apn1, APE1 knockout mouse blastocysts and 
antisense-expressing human cells are hypersensitive to γ rays and oxidizing agents, 
whereas Apn1 yeast mutants are at best mildly sensitive to γ rays and oxidizing agents 
like (e.g. H2O2) [105]. These results suggest that there might be other species-specific 
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factors implicated in alternative repair mechanisms that need to be taken into 
consideration when assessing the right model (yeast or mammalian cells) to study DNA 
damage response to certain genotoxic agents. 
Besides its activity in the BER pathway, APE1 was shown to be the damage-specific 
endonuclease in the nucleotide incision repair (NIR) pathway, a known feature in Endo-
IV family of endonucleases [112]. NIR pathway was proposed as an alternative pathway 
to classic BER. In this pathway, APE1 nicks oxidatively damaged DNA (e.g. 5,6-
dihydro-2’-deoxyuridine, 5,6-dihydrothymidine (DHT), 5-hydroxy-2’-deoxyuridine, 
alpha-2’-deoxyadenosine and alpha thymidine adducts) in a DNA glycosylase-
independent manner, generating 3’-OH and 5’ phosphate. This mechanistic feature is 
distinct from DNA glycosylase-mediated BER and has the advantage of avoiding the 
genotoxic intermediates (i.e. AP sites) generated in the BER pathway [113].                                 
A recent study showed that APE1 appears to suppress the activation of poly(ADP-ribose) 
polymerase 1 (PARP1) during oxidative damage repair which promotes cell survival 
[114]. 
Furthermore, some groups showed that APE1 also possesses 3’ to 5’ exonuclease activity 
which plays a role in the excision of deoxyribonucleoside analogs from the DNA [115, 
116]. If this is the case, the inhibition of this activity could have implications in treating 
some cancers where nucleoside analogs such as gemcitabine are used. Conflicting data 
are present in the literature regarding this latter activity of APE1. Some groups showed 
that this activity is structure specific and presented a preference for 3’-mismatched 
nucleotides [115, 117, 118], while others showed that it presented no exonuclease activity 
against blunt ended dsDNA [93, 119]. Interestingly, the yeast Apn1 is endowed with a 
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well-characterized 3’ to 5’ exonuclease activity that is capable of removing incorporated 
8-oxo-G from the DNA, a function that possibly APE1 might have [120].    
Given the many DNA repair functions of APE1, it is clear that this enzyme is 
fundamental to the maintenance of the genome and survival of cells. Hence the 
observation that even in the absence of exogenous DNA damage, siRNA directed against 
APE1 results in a decrease in proliferation, an increase in AP sites and increased levels of 
apoptosis [121]. 
 
6.2 APE1:  a Redox enzyme 
In addition to its role in DNA repair, APE1 has also been implicated in transcription 
regulation by reducing and thus activating many transcription factors. APE1 was first 
shown to reduce the conserved cysteine residues in Fos and Jun. Fos and Jun form a 
heterodimeric complex that regulates gene transcription by binding to the activator 
protein-1 (AP-1) DNA sequence motif. APE1 activation of Fos and Jun stimulates AP-1 
DNA-binding activity [91].  
 Later reports have revealed a similar role of APE1 in activating p53, Fos, Jun, nuclear 
factor-κB (NF-κB), PAX (paired box-containing family of genes), hypoxia inducible 
factor-1α (HIF-1α), HIF-1-like factor and others [105]. The biological implication of 
these transcription factors activation is no fully clear yet, but what is known so far that 
APE1 redox function facilitates the DNA binding of some of these transcription factors 
or change the transcriptional activity of others [105]. Interestingly, it was demonstrated 
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that p53 binding to DNA and the subsequent transcriptional activation of p21, BAX or 
cyclin G is dependent on APE1. Moreover, APE1 protein was reported to stimulate p53 
activity by both redox-dependent and -independent means [122].   
APE1 has also been implicated in  a number of other redox activations, one of which is 
the activation of bioreductive drugs  requiring reduction for their activity [123]. Hence 
APE1 acts as a redox factor that senses the redox state of the cell.   
APE1 redox activity requires the N-terminal region of the protein as the truncation of the 
62 N-terminal residues renders the enzyme redox deficient (Figure 15 and 16) [124, 
125]. It is noteworthy that human APE1 has 61 N-terminal additional amino acids that 
are not present in the E.coli Exo III. It was proposed that APE1 redox activity involves a 
cysteine residue(s) [124] that according to LJ Walker et al. was Cys 65 that forms a 
disulfide bridges with Cys 93 [125]. However, several reported crystal structures of 
APE1 showed three different observations contradicting the latter finding. First, no 
disulfide bridges were found in the crystal structures. Second, Cys 65 is buried inside the 
protein and is not accessible by the target transcription factors reduced by APE1 [77, 126, 
127]. Third, all the reported APE1 crystallographic lattices are similar, suggesting the 
absence of conformational changes that could reposition Cys 65 [77]. Moreover, mice in 
which Cys 64 (equivalent to human Cys 65) is mutated to Ala show no developmental 
defects [128]. Thus, the mechanism by which Cys 65 acts in APE1 reduction of 
transcription factor needs to be further investigated.  
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6.3 Importance of APE1 cellular functions 
Given the mild phenotype seen in other AP endonuclease-deficient organisms, lethality of 
APE1 -/- mice and knockout cells was a big surprise. 
Unlike bacteria and yeast, which tolerate the complete loss of AP endonuclease activity 
with little consequence unless challenged with DNA damaging agents, APE1 knockout in 
mice is lethal at early embryonic stages, E3.5–E9.5 [129, 130]. 
 However, heterozygous mutant mice developed into adulthood without any apparent 
abnormalities [129]. Although it was not clear at the time which function(s) of APE1 is 
contributing to the lethality phenotype seen in mice, a recent study using a specific 
inhibitor of APE1 redox function demonstrated that APE1 may play a role in normal 
embryonic hematopoiesis and that its redox function, but not the DNA repair 
endonuclease activity, is critical in normal embryonic hematopoietic development [131]. 
On the contrary, evidence for importance of DNA repair function was presented by 
another group who showed that epiblast cells have fragmented nuclei and undergo 
apoptosis and that explanted homozygous APE1-null blastocysts displayed increased 
sensitivity to γ-irradiation [130].  
Further research showed that loss of APE1 is lethal at the level of the cell. Human cells in 
which APE1 is deleted by a microinjection of a Cre expression plasmid, undergo 
apoptosis within 48 hours [132].                                                                                            
Since APE1 deletion is lethal, many groups manipulated APE1 expression levels by 
either downregulation or overexpression. RNA interference (RNAi) knockdown resulted 
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in decreased cell proliferation and apoptosis which was correlated with an accumulation 
of AP sites [121]. Moreover, lower levels of APE1 render mammalian cells 
hypersensitive to MMS and H2O2 [133]. Importantly, the defects seen in knockdown cells 
were rescued by the expression of the yeast Apn1. Thus, the AP endonuclease activity of 
APE1 was shown to be essential for cell viability.  
To date, many types of inhibitors of APE1 activities have been discovered. Lucanthone 
and 7-Nitroindole-2-carboxylic acid (NCA) were shown to be direct inhibitors of APE1 
DNA repair activity [70, 134]. Recently, a novel quinone derivative that inhibits APE1 
redox activity was identified, namely E3330 ([(2E)-3-[5-(2,3dimethoxy-6-methyl-1,4-
benzoquinolyl)]-2-nonyl-2-propenoic acid]) [135]. 
In this context, a beneficial effect of the reduction of APE1 levels is to sensitize cells to 
chemotherapeutic agents such as bleomycin, carmustine, gemcitabine [136-138].  
On the other hand, APE1 overexpression in human cells enhances tumour resistance to 
DNA damaging drugs and radiotherapy, as expected, a phenotype seen in many cancer 
cells [139]. 
 
6.4 Regulation of APE1 Activity 
APE1 is regulated at two different levels: transcriptional and post-translational. 
Regulation of the activity of an essential enzyme like APE1 is of great importance for the 
cell to respond properly to DNA damage and to other diverse stimuli where it is involved. 
 
29 
6.4.1 Gene expression regulation 
APE1 transcription is known to be induced by ROS. This regulation was proposed to 
happen in two steps: first APE1 translocates from the cytoplasm to the nucleus. Second, 
de novo protein synthesis takes place via transcriptional activation at the promoter level 
[104, 140-142]. Interestingly, APE1 was shown to autoregulate its own transcription by 
binding to its own promoter followed by inhibition of transcription at the level of its 
negative calcium regulatory element (nCARE) [143].  
 
6.4.2 Post-translational modifications 
APE1 is an abundant protein (~104–105 copies/cell) within eukaryotic cells and with a 
relatively long half-life of about 8 hours [144]. Therefore, the needed regulation of this 
multifunctional enzyme must lie in the many post-translational modifications that this 
enzyme undergoes. 
  
6.4.2.1 APE1 structure 
The N-terminal region contains the nuclear localization signal (NLS) and also appears to 
regulate the DNA binding activity of many transcription factors in vitro. Particularly, the 
residues 43-62 are necessary for APE1 redox activity [91, 122, 124, 125]. 
The active site residues of APE1 have been determined by site-directed mutagenesis and 
by analysis of sequence conservation between APE1 and Exo III [72, 145, 146]. There is 
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an absolute requirement for divalent metal ions for APE1 catalytic activity, with a distinct 
preference for magnesium [145]. Figure 8 highlights APE1 active site, illustrating the 
main residues implicated in its catalytic activity along with the ones critical for binding to 
AP sites in DNA.  
Comparison of the crystal structures of APE1 and Exo III reveals three loop regions that 
act in AP site recognition and cleavage. While many structural similarities between 
APE1, Exo III and the bovine endonuclease Deoxyribonuclease I (DNase I) have been 
reported, DNase I does not have an AP endonuclease activity since it has different loops 
and α-helices from APE1 and Exo III. These loops contribute to the positively charged 
grooves that form the DNA-binding faces of APE1 and Exo III thus dictating their 
specificity as AP endonucleases [77, 81, 109].  
Although they are structurally unrelated enzymes, analysis of the crystal structures of 
APE1 and the bacterial Endo IV binding to an AP site shows that both enzymes orient the 
AP site via positively charged surfaces and insert loops into the DNA base stack, bending 
and kinking the DNA to promote flipping of the AP site into a sequestered enzyme 
pocket that contains only the damaged nucleotide [109]. 
His309 is considered the catalytic residue of APE1. It acts as the general base to abstract 
a proton from a water molecule, while Asp283 orients the imidazole ring of His309 and 
stabilizes its transiently- positive charged state along with Mg2+. The resulting hydroxide 
ion then attack the 5’ phosphate of an AP site via an inversion of configuration. The 
mutations of His309 to Asn and of Asp283 to Ala result in the elimination of enzymatic 
activity, showing the importance of these two residues for APE1 activity [77]. The 
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mechanism of the phosphodiester bond cleavage at the 5’ of an AP site is summarized in 
Figure 9. 
                                                                                     
Figure 8. APE1 active site interactions with the AP site. Adapted from [77].  
Figure 9. AP site cleavage reaction mechanisms by APE1catalytic site residues. 
Adapted from [77]. 
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6.4.2.2 Phosphorylation 
It was demonstrated that APE1 is a substrate for phosphorylation by different kinases 
such as serine/threonine casein Kinases (CK) I and II and protein kinase C. However, 
phosphorylation uniquely by CK II was shown to inhibit the AP endonuclease activity of 
APE1 on AP sites [147]. Conversely, two years after this discovery another group 
showed that this phosphorylation by CK II does not have any impact on the DNA repair 
capacity of APE1, instead it enhance the redox function of APE1 shown by the increase 
of AP-1 binding to DNA [148].  
 
6.4.2.3 Acetylation 
p300 is a transcriptional co-activator that was shown to acetylate APE1 at Lys6 and Lys7 
in vitro and in vivo in a Ca2+-dependent manner. This modification enhances APE1 
binding to nCARE which was shown to downregulate the parathyroid hormone (PTH) 
expression [149]. This acetylation is reversed by class I histone deacetylases (HDACs). 
Moreover, it was demonstrated that APE1 acetylation is needed for the activation of the 
Phosphatase and tensin homolog (PTEN) gene [150]. 
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6.4.2.4 Ubiquitination 
A recent discovery identified APE1 as a novel target of ubiquitination. This modification 
occurs on Lys residues of the N-terminus of the protein and involves the E3 ubiquitin 
ligase mouse double minute 2 (MDM2), in a p53-dependent manner. The ubiquitinated 
APE1 was shown to be predominantly present in the cytoplasm compared to nuclear 
localization of the unmodified protein. Although it was proposed that cytoplasmic 
localization of the ubiquitinated APE1 might be an indication of either its degradation or 
an alteration of its function, the effect of ubiquitination on APE1 is still not clear [151]. 
 
6.4.2.5 Nitrosylation 
Oxidative stress was shown to have an effect on APE1 activity. Interestingly, nitrosative 
stress was also shown to modify this enzyme. The nitrosation of APE1 on Cys93 and 
Cys310 induces the translocation of APE1 to the cytoplasm, a phenomenon reversed by 
treatment with reducing agents [152]. The biological implication of this modification 
needs more investigation. 
 
6.4.2.6 Redox regulation   
In addition to the post-translational modifications listed above, APE1 diverse activities 
were found to be regulated by the reduction and oxidation. Thioredoxin (TRX) is a 
pleiotropic cellular factor that has thiol-mediated redox activity implicated in many 
cellular processes, including the reduction and activation of APE1 redox function [153]. 
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The reduction of oxidized APE1 by TRX leads to intensified APE1-mediated p53 
activation and enhanced AP-1 DNA binding [154]. Although the target residues of the 
reduction on APE1 are not known, they may include Cys65 and Cys93 since these sites 
are thought to be redox sensitive [125]. Moreover, it was shown that the redox state of 
APE1 affects its AP endonuclease activity in vitro and that this modification involves a 
specific cysteine residue of this enzyme [155].  
Recently in our laboratory, we showed that APE1 interacts directly with the glycolytic 
enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which converts the 
oxidized form of APE1 to the reduced active form, thus maintaining its AP endonuclease 
activity to repair AP sites [156]. Investigating the implications and aspects of this novel 
finding will be the object of my research project. 
 
7. GAPDH: a multifunctional protein 
GAPDH is a tetrameric enzyme (Figure 10) that uses the oxidized form of nicotinamide 
adenine dinucleotide (NAD+) to converts glyceraldehyde-3-phosphate to 1,3-
bisphosphoglycerate, releasing NADH [157]. GAPDH is regarded as a housekeeping 
gene whose transcript level remains constant under most experimental conditions, and it 
has been frequently used as an internal control in studying the regulation of gene 
expression. Mounting evidence, however, has started to support the multi-functionality of 
this enzyme, identifying roles in a variety of cellular processes, independent from its 
glycolytic role. 
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GAPDH was shown to have phosphotransferase/kinase activity that serves to 
phosphorylate other proteins [158-162]. Interestingly, GAPDH was shown to have 
autophosphorylation activity as well [163]. Other new functions includes regulation of 
the cytoskeleton [164], membrane fusion and transport [165, 166], transport of nuclear 
RNA [167], glutamate accumulation into presynaptic vesicles [168], activation of 
transcription in neuronal cells [169], and protection of telomeres against chemotherapy-
induced degradation [170]. Moreover, GAPDH exhibited a DNA repair activity by acting 
as a Uracil DNA glycocylase (UDG) which removes mis-incorporated uracil from the 
DNA [171, 172].   
Notably, GAPDH was demonstrated to play a crucial role in neuronal apoptotic cell death 
that has pathophysiological implications in many neurodegenerative diseases such as 
Alzheimer’s disease (AD) [173], Huntington’s disease (HD) [174] and Parkinson’s 
disease (PD) [175].  
Under oxidative stress, GAPDH undergoes oxidation and manifests a reduction in its 
enzymatic activity [176]. This oxidation also enhances the binding of GAPDH to RNA 
and DNA [177]. Treatment with H2O2 induces the translocation of GAPDH from the 
cytoplasm to the nucleus in mammalian cells [178]. Moreover, a recent study showed that 
nitric oxide (NO) induces GAPDH nuclear localization followed by its acetylation by 
p300/CBP that will result in the transcriptional activation of many genes such as p53 
[179]. Considering all of these alterations of function upon oxidative conditions, GAPDH 
seems to be playing an important role in cellular response to oxidative stress. 
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Figure 10. Overall structure of GAPDH homotetramer. Adapted from[180].   
8. Research project  
8.1 Background 
As described earlier, APE1, a member of the Exo III family, was found to be the major 
AP endonuclease present in mammalian cells, unlike the Endo IV family members that 
are only present in lower organisms. Many previous attempts to identify an Endo IV 
enzymatic activity in mammalian cells that acts independently of Mg2+ failed to detect it.  
It was recently documented in our laboratory [156] a trial to identify such activity using 
total cell extracts derived from human lung fibroblast that resulted in the detection of a 
weak Mg2+- independent that was reflected by the cleavage of a 42-mer [γ-32P] labeled 
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synthetic oligonucleotide substrate containing a single AP site. Subsequent purification 
steps followed by mass spectrometry analysis of the protein fraction having this activity 
revealed the presence of GAPDH protein. Purified recombinant GAPDH lacks an AP 
endonuclease activity, the only explanation to the observed activity is that GAPDH was 
co-purified with another protein possessing this activity, namely APE1. Since APE1 has 
an Mg2+-dependent activity, a possible explanation is the EDTA concentration in the 
buffer used was not enough to chelate all the Mg2+ from the extract in the reaction, 
leaving some APE1 enzymes active, contributing to the detected AP endonuclease 
activity. 
Further experiments showed that GAPDH interacts with APE1 in vivo and in vitro. This 
interaction causes the conversion of the oxidized and AP endonuclease deficient APE1 to 
a reduced and active protein capable of cleaving AP sites. This reducing potential of 
GAPDH was shown to be dependent on Cys 152 residue of its active site. Other reports 
showed that APE1 exists as heterogeneous molecules that are either reduced or oxidized 
[153]. Moreover, it was reported that APE1 can be oxidized by H2O2 to the inactive form, 
a phenomenon partially reversed by the treatment with dithiothreitol (DTT) [155].  
Interestingly, siRNA knockdown of GAPDH in HCT116 cells caused sensitivity to MMS 
and bleomycin, two drugs known to create DNA lesions that are repairable by APE1, but 
not to UV irradiations which produces bulky lesions. A similar phenotype was observed 
when using siRNA directed against APE1 [138]. Furthermore, total extracts of these cells 
showed a reduced AP endonuclease activity. They also exhibited an increase in 
spontaneous AP sites frequency in their genomic DNA.  
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8.2 Hypothesis 
Since GAPDH interaction with APE1 activates the AP endonuclease activity of this 
enzyme in vitro, and since the deficiency in GAPDH sensitized cells to DNA damaging 
drugs, induced an increase in AP sites formation and reduced the AP endonuclease 
capacity, we hypothesize that deficiency in GAPDH affects cell cycle progression and 
APE1 cellular distribution.  
Moreover, since GAPDH activates APE1 by reduction, we postulate that this reduction 
occurs at the level of disulfide bridge(s) formed between APE1 cysteine residues. 
 
8.3 Objectives 
Objective 1: To determine whether activation of APE1 by 
GAPDH is required for efficient cell cycle progression  
It is critical for dividing cells to ensure their DNA integrity in order to avoid any 
inherited mutations in daughter cells. DNA lesions activate checkpoint pathways that 
regulate specific DNA repair mechanisms during different phases of the cell cycle. 
Checkpoint-arrested cells resume their cell cycle progression once the damage has been 
repaired, whereas cells with unrepaired DNA lesions undergo permanent cell cycle arrest 
or apoptosis. 
Since GAPDH Knockdown cells showed a defect in proliferation and since this 
knockdown affected the DNA repair capacity of the cells, i.e. AP endonuclease activity, 
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we studied the cell cycle progression of GAPDH knocked down cells and we found that 
GAPDH knockdown cells had a delay in progressing through the S phase as compared to 
control cells. 
 
Objective 2: To determine whether depletion of GAPDH affects 
the subcellular localization of APE1 
Although APE1 is mainly a nuclear protein, it has been reported that its cellular 
distribution varies from normal cells to cancer cells, as it was shown that APE1 localizes 
to the cytoplasm in cancer cells as in the case of lung [181], ovarian [182], thyroid[183], 
and breast cancer[184]. This localization has been linked to higher aggressiveness of the 
tumor. It was also shown to be present in the endoplasmic reticulum (ER) and the 
mitochondria [185, 186].  
Moreover, upon oxidative stress some DNA repair enzymes like OGG1 and APE1 
localize to nuclear speckles, structures that are present between chromatin domains 
enriched with RNA processing and transcription proteins [187].  
 For these reasons, we investigated the cellular distribution of the presumably oxidized 
and inactive APE1 in GAPDH knock down cells. We found that APE1 forms foci-like 
structures in GAPDH deficient cells.  
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Objective 3: To identify the redox-sensitive cysteine(s) of APE1 
that is reduced by GAPDH 
APE1 has seven cysteine residues at positions 65, 93, 99, 138, 208, 296 and 310, some of 
which were shown to be important for its redox activity (Cys 65). Since GAPDH was 
shown to reduce APE1, we expect that this reduction occurs at the level of one or more of 
these cysteines, causing a reduction of a disulfide bridge(s) inducing a conformational 
change in APE1 structure which allows it to be active and capable of cleaving AP sites. 
To identify the cysteine residue (s) involved we mutated each of the 7 cysteine to alanine, 
which cannot form disulfide bridges and assayed for the activity of these mutants in vitro 
and in the cells. We specifically asked whether one or more cysteine mutant would 
maintain its AP endonuclease activity under oxidative conditions in the absence of 
GAPDH and show no enhancement in AP endonuclease activity or redox state when 
GAPDH is added. Hence the expression of the candidate mutant(s) should rescue the 
defect in proliferation seen in GAPDH knock down cells. 
Chapter 2: Materials and Methods 
1. Expression and Purification of His-APE1 
variants 
His-APE1 was cloned in pET14-b vector under a T7 promoter and expressed in BL21 
(DE3) pLysS strain and purified using Talon Metal Affinity column (Clonetech) 
according to manufacturer instructions with some modifications. Briefly, BL21 pLysS 
E.coli cells expressing His-APE1 (wild type or cysteine or active site mutants) were 
streaked out on Luria Broth (LB) agar plates containing Ampicillin  (100 μg/mL), a 
single colony was inoculated in 20 mL of LB containing Ampicillin (100 μg/mL) for 
overnight incubation at 37˚C with shaking (180 rpm). Next morning, 10mL of the 
overnight culture was subcultured in 1L of LB and grown up to O.D= 0.5. IPTG (0.4mM) 
was added to the culture and left for two hours at 37˚C with shaking. Cells were 
harvested by centrifugation at 6000 rpm for 15 minutes at 4˚C. Cell pellet was 
resuspended in the washing buffer (50 mM sodium phosphate pH 7.0, 300mM NaCl) 
containing protease inhibitors (Invitrogen) and is subjected to sonication for short bursts 
on ice at 50% amplitude (Branson Digital Sonifier ®) to lyse the cells. Cell lysate was 
then centrifuged at   13,000 rpm for 20 minutes at 4˚C. The purification steps were done 
at room temperature. The supernatant was loaded onto a column made of 1 ml of Talon 
metal affinity resin (Clonetech)  and the flow through was collected and passed again on 
the column to maximize the amount of binding proteins. The column was washed with 
42 
the washing buffer containing protease inhibitors. His-tagged bound proteins were eluted 
by elution buffer (50mM sodium phosphate pH 7.0, 300nM NaCl, 150mM Imidazole), 
and collected as fractions of 500 μL each.  Protein concentration and purity were 
estimated by Bradford assay and SDS-PAGE subsequently. The purified proteins were 
dialyzed against 1L of the storage buffer (20mM sodium phosphate pH 7.0, 100mM 
NaCl, 1mM EDTA, 10% Glycerol) at 4˚C.  
 
2. Expression and purification of GST-GAPDH 
GST-GAPDH was cloned in pGEX-4T-1 (Amersham Biosciences) and expressed in 
DH5α. Cells were cultured and proteins were extracted as previously described in section 
1 of Materials and Methods except for protein extracts that were loaded on glutathione-
Sepharose 4B mini columns (GE Healthcare). The column was washed with the wash 
buffer (50 mM Tris-HCl pH 7.0, 300mM NaCl). And the proteins were eluted with 
50mM Tris-HCl pH 9.0, 20mM reduced glutathione. 
  
3. Silver staining  
Immediately after electrophoresis, the SDS-PAGE was fixed in a solution of 50% 
Methanol, 10% acetic acid for 30 minutes.  The gel was then washed three times in 15% 
methanol for 10 minutes each with gentle shaking. The gel was then transferred to 7.5% 
Glutaraldehyde solution and incubated at 37˚C for 30 minutes, with gentle shaking. 
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Another washing step with 15% methanol and distilled water subsequently for 15 minutes 
each, for three times. The Gel was then stained with a silver nitrate (AgNO3) for 10 
minutes with gentle shaking. To remove excess silver nitrate, the gel is washed with 
water until the color of the solution becomes clear. To develop the gel, developing 
solution (0.005% citric acid, 0.2% formaldehyde) was added to the gel with gentle 
shaking, the staining should take place in the first 10 to 20 minutes of the incubation. A 
stop solution (5% acetic acid) was added to stop further staining. 
 
4. Western Blot Analysis 
Western blot analysis was performed according to standard protocols. For purified His-
APE1 and GST-GAPDH in vitro assays, purified proteins concentrations were 
determined using the Bradford analysis. Proteins were loaded onto a 10% SDS 
polyacrylamide gel, which was run at 100 V. The proteins were then transferred to a 
nitrocellulose membrane at 100 V for 1 hour. The membrane was blocked with 5% of 
skim milk in TBSET (6.05 g Tris-Base, 43.83 g NaCl, 1.85 g of EDTA and 500 μl tween 
20 in 500 ml of distilled water and then probed overnight at 4°C with mouse monoclonal 
anti-His (Santa Cruz biotechnology) antibody at a concentration of 1/2500 in 5% milk. 
Three successive washes (10 min each) with TBSET were then performed to wash all 
excess of the primary antibody. After the last wash, the membrane was incubated for 1 
hour with the anti-mouse polyclonal antibody and was followed by 3 washes of 10 min 
each with TBSET.  Finally the membrane was incubated for 1 min in chemiluminescence 
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reagent and developed using a FujiFilm Intelligent Dark Box and images were acquired 
with a LAS-3000 camera and the Image Reader LAS-3000 Lite software. 
 
5. Site-Directed Mutagenesis 
Site-directed mutagenesis (QuikChange® lightning kit, Stratagene) was used according to 
the manufacturer’s instructions to mutate APE1 seven cysteines and the active site 
residues to alanine using native His-APE1 in pET-14b as the template. The primers 
corresponding to every mutant are listed in table II. Briefly, prior to PCR, sample 
reactions were prepared as follows:  
• 100 ng of the dsDNA template containing plasmid 
• 125 ng of  each of the mutagenic primers, forward and reverse 
• dNTP mix 
• reaction buffers 
• 1 μl of QuickChange® Lightning enzyme 
Each reaction is then cycled using the following parameters: 
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Segment Cycle(s) Temperature (°C) Time 
1 1 95 2 min 
2  
18 
95 20 sec 
60 10 sec 
68 2min 30sec 
3 1 68 5 min 
 
The PCR products are digested with Dpn I restriction enzyme to degrade the template 
plasmid. XL10-Gold® Ultracompetent cells (Stratagene) are transformed with 2 μL of the 
Dpn I-treated PCR product. Then transformed cells are grown in NZY+ broth for 2 hours 
at 37°C with shaking (225rpm). 100 μL of the grown culture are plated on LB-ampicillin 
agar plates and incubated at 37°C overnight. Next morning, several single colonies are picked 
and grown in LB-ampicillin broth followed by plasmid extraction following the 
manufacturere’s protocol (Qiagen Qiaprep® spin Miniprep kit). The extracted plasmids 
were verified for the presence of the desired point mutation by DNA sequencing analysis.  
The primers used for sequencing of APE1 created variants are as follows: 
APE1-C65A variant: 5’-GAAGAGTAAGACGGCCGCAAAG-3’ 
APE1-C93A and C99A variant: 5’-CAGATCAGAAAACCTCACCCAG-3’ 
APE1-C138A: 5’- CAGAGAACAAACTACCAGCTG-3’ 
APE1-C208A: 5’- GCTGGTAACAGCATATGTACCT-3’ 
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APE1-C296A and C310A:5’- CACCTCTACCCCAACACAC-3’ 
A control reaction provided by the manufacturer was used to verify the efficiency of 
mutant plasmid generation.  
 
6. Bacterial Transformation 
For plasmid amplification and cloning purposes we prepared bacterial competent cells as 
follows: 1 mL of an overnight culture was subcultured in 100 mL for 4 hours at 37°C. 
The obtained bacterial pellet was incubated with 100 mM Calcium Chloride (CaCl2) on 
ice for at least one hour. To 50 μL of prepared competent bacteria, 1 μg of the desired 
plasmid DNA was added and left to incubate on ice for 30 minutes. Then the bacteria-
DNA mixture was incubated at 42°C for 90 seconds for heat shock. 1mL of LB broth was 
added to the transformation reaction and left to incubate at 37°C with shaking for 2-4 
hours. The transformed bacteria were then plated on selective LB agar plates (containing 
either ampicillin (100 μg/ml) for pET-14b vector, or Kanamycin (50 μg/ml) for pEYFP-
N1 vector).  
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APE1 variant Mutagenic Primers 
 
APE1-C65A 
F: 5’-CCACACTCAAGATCGCCTCTTGGAATGTGGATG-3’ 
R: 5’-CATCCACATTCCAAGAGGCGATCTTGAGTGTGG-3’ 
 
APE1-C93A 
F: 5’-GCCCCAGATATACTGGCCCTTCAAGAGACC-3’ 
R: 5’-GGTCTCTTGAAGGGCCAGTATATCTGGGGC-3’ 
 
APE1-C99A 
F: 5’-GCCTTCAAGAGACCAAAGCCTCAGAGAACAAAC-3’
R: 5’-GTTTGTTCTCTGAGGCTTTGGTCTCTTGAAGGC-3’ 
 
APE1-C138A 
F: 5’-GCTTTCCCGCCAGGCCCCACTCAAAGTTTCTTACG-3’ 
R:5’-CGTAAGAAACTTTGAGTGGGGCCTGGCGGGAAAGC-3’ 
 
APE1-C208A 
F: 5’-CCTTGTGCTGGCCGGAGACCTCAATGTG-3’ 
R: 5’-CACATTGAGGTCTCCGGCCAGCACAAGG-3’ 
 
APE1-C296A 
F: 5’-CTCTCTGTTACCTGCATTGGCCGACAGCAAGATCCG-3’ 
R: 5’-CGGATCTTGCTGTCGGCCAATGCAGGTAACAGAGAG-3’ 
 
APE1-C310A 
F: 5’- CCTCGGCAGTGATCACGCCCCTATCACCCTATAC-3’ 
R: 5’GTATAGGGTGATAGGGGCGTGATCACTGCCGAGG-3’ 
 
APE1-H309A 
F:5’GGCCCTCGGCAGTGATGCCTGTCCTATCACCCTATACC3’
R:5’GGTATAGGGTGATAGGACAGGCATCACTGCCGAGGGCC3'
 
APE1-D210A 
F: 5’- CCTTGTGCTGTGTGGAGCCCTCAATGTGGCACAT-3’ 
R: 5’ATGTGCCACATTGAGGGCTCCACACAGCACAAGG-3’ 
 
APE1-D308A 
F: 5’- GGCCCTCGGCAGTGCCCACTGTCCTATCACC-3’ 
R: 5’ GGTGATAGGACAGTGGGCACTGCCGAGGGCC-3’ 
Table I. Site-directed mutagenic primers used to create Cys to Ala, His to Ala, Asp to Ala 
point mutations. They were designed according to manufacturer’s recommendation, (Stratagene). 
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7. Cloning of APE1 variants in pEYFP-N1 
APE1 variants were cloned in pEYFP-N1 vector that has and enhanced yellow 
fluorescent protein (EYFP) for expression in mammalian cells. Briefly, APE1 wild type 
and variants were amplified by PCR from the pET-14b construct. Primers were designed 
in a way to introduce APE1 between Hind III and BamH I in fusion with the EYFP gene 
by removing APE1 stop codon from the reverse PCR primer. A Kozak sequence 
(underlined) was added upstream of the start codon in the forward primer to enhance the 
translation of the resulting mRNA. Two additional nucleotides were added to the reverse 
primer downstream of BamH I restriction site, to put the insert in frame with the EYFP 
gene. 
Oligo sequence for APE1 variants cloning in pEYFP-N1: 
F: 5’- ATACGATAGC-AAGCTT- GCCACCATGCCGAAGCGTGGGAAAAA-3’ 
R: 5’-AGGCTGAGAT-GGATCCAG–CAGTGCTAGGTATAGGGTGATAGG- 3’ 
PCR was conducted in the presence of Pfu DNA polymerase (Feldan-Bio). PCR 
parameters used are the following: 
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Segment Cycle(s) Temperature (°C) Time 
1 1 94 3 min 
 
2 
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94 30 sec 
60 30 sec 
72 1min 
3 1 72 10 min 
 
PCR products were ran on a 1% agarose gel, the DNA bands corresponding to APE1 
variants genes are cut and DNA purified using GeneClean method that consists of 
incubating the DNA to be purified with powdered suspension of glass, called glass milk, 
to which DNA binds in high salt concentration (6 M NaI). The agarose band was 
incubated at 55°C for 10 minutes with NaI solution to dissolve it. Then the melted 
solution was allowed to cool to room temperature for 5 minutes. 5 μL of the glassmilk 
suspension was added to the melted NaI- agarose solution containing the DNA and was 
incubated at room temperature for 5 minutes to allow the DNA binding to the glassmilk. 
Subsequently the glassmilk was pelleted by centrifugation and washed twice with NEW 
wash buffer (50% ethanol in TE pH 7.5, 100 mM NaCl). Elute the bound DNA from the 
glassmilk using 10 μL of water or Tris-EDTA (TE).  
The purified PCR products of APE1 variants and the empty pEYFP-N1 vector were 
digested with the two restriction enzymes, Hind III and BamH I for 1 hour 30 minutes at 
37°C to give compatible ends for ligation. The digestion products were purified by the 
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previously described GeneClean method. Ligation mixtures containing the digested PCR 
products and empty vector were incubated with T4 DNA ligase (New England BioLabs) 
overnight at 16°C (20 μL reaction). 
Transformation of DH5α competent cells with 4 μL of the ligation reaction was 
conducted the next morning, using the previously described transformation protocol. 
Transformed bacteria were plated on LB-kanamycin agar plates for selection of the 
positive clones. 
Single colonies were grown in LB-kanamycin broth and plasmid extraction was done 
according to the manufacturer instructions (Qiagen). Double digestion using Hind III and 
BamH I was done to verify the success of the cloning. The digestion product was 
assessed for the presence of the insert (APE1 variants) by electrophoresis on an agarose 
gel. 
 
8. Cloning of native Apn1 and its inactive mutant 
E158G in pEYFP-N1 
Apn1 was amplified from p3xFLAGCMV10-Apn1 (a gift from Dr Bruce Demple, 
Harvard Medical School) as described in section 7. Apn1-E158A was amplified from 
pYES 2.0 vector. Primers used for cloning in pEYFP-N1 vector are listed below. It was 
cloned in fusion with EYFP gene. The cloning procedure including the PCR, the 
digestion, ligation and verification of the cloning were done as described in section 7 for 
APE1 variants cloning.  
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Primers used for Apn1 and its variant Apn1-E158G cloning in pEYFP-N1: 
F: 5’-AATCGATGCT-AAGCTT-GCCACCATGCCTTCGACACCTAGC-3’ 
R: 5’-AGGCTGAGAT-GGATCCAG- TTCTTTCTTAGTCTTCCTCTTCTT-3’ 
  
9. HCT116 Cell culture 
Human colon carcinoma HCT116 cell line was kindly provided by Dr.Elliot Drobetsky 
(University of Montreal). They were culture in Dulbecco's Modified Eagle Medium 
(DMEM) (Wisent Inc.) complemented with 10% of fetal bovine serum (FBS) (Wisent 
Inc.) and 0.1mg/ml penicillin, and 0.1 mg/ml streptomycin. Cells were incubated at 37°C 
and 5% CO2. The media was changed every 48 hours. 
 
10. GAPDH Knockdown by siRNA 
Human Silencer GAPDH siRNA (Ambion) that targets the 5' medial region of GAPDH 
mRNA sequence was used to knock down the expression of GAPDH in HCT116 cells. 
The cells were cultured in Petri plates and transfected with 75 nM of GAPDH siRNA 
using Lipofectamine 2000 (Invitrogen) in Opti-MEM (Invitrogen) according to the 
manufacturer’s protocol. Negative control (75 nM) that has no homology to any known 
gene was also included in the transfection. The plates were incubated at 37°C in 5% CO2 
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for 4 h, after which the complete growth medium was added, and the cells were proceed 
for subsequent assays. 
 
11. Protein extraction form HCT116 
HCT116 adherent cells are collected from the Petri plates using a cell scraper and not 
trypsin, to avoid any possible protein degradation. Cell were washed with cold PBS and 
only the pellet was frozen at -80°C if the protein extraction was not done on the same 
day. For protein extraction, 200 μL of RIPA buffer (NaCl, EDTA, Tris Base, 1% 
Deoxycholic acid, 1% Nonidet p-40 in millipore water) supplemented with protease 
inhibitors and then added to the pelleted cells and incubated on ice for 1 hour. The lysed 
cells are centrifuged at 12,000 rpm at 4°C for 30 minutes. The supernatant was then 
stored at -80°C until used. Protein concentration was estimated using Bradford method.  
 
12. Western blot to verify Knock down of GAPDH 
For the verification of GAPDH Knock down in HCT116 cells, total cell extracts were 
quantified using Bradford protein estimation method, and equal amounts were loaded on 
a 10% SDS-PAGE and proceeded for western blot analysis as described in section 4 
except for the use of the monoclonal mouse anti-GAPDH followed by probing with anti-
mouse antibody. The membrane was probed with anti-tubulin antibody as a loading 
control. 
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13. HCT116 plasmid DNA transfection 
Transfection of HCT116 with 1-2 μg of pEYFP-N1 plasmid carrying APE1 different 
variants was done as previously described in section 10 using lipofectamine 2000 and 
Opti-MEM media. The expression of APE1-EYFP proteins was detected after 4 hours of 
the transfection under a fluorescent microscope.  
 
14. Establishing Stable Clones expressing APE1 
variants, Apn1 and Apn1-E158G  
HCT116 were transfected as described in section 10. 48 hours after transfection, G418 
(Neomycin) (Wisent Inc.) was added to the media of the transfected cells at a 
concentration of 150 μg/mL for selection of the positive clones expressing the APE1- 
EYFP or Apn1-EYFP that has a neomycin resistant gene as a marker for selection. A 
serial selection of positive cells was done by increasing concentrations of G418 (150, 
200,250, 350, and 400 μg/mL) over three weeks, the approximate time needed for single 
colonies of transfected cells expressing differential amounts of the protein of interest. 
Cell sorting (FACS Aria III, BD) was used to pick single cells that were then cultured in 
200 μL of media containing 200 μg/mL of G418, and then subcultured in 1ml, 2ml, 5ml 
and 10 mL successively. G418 at 200 μg/mL was used for maintenance of the stably 
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transfected cells in culture. The efficiency of the transfection was assessed under the 
microscope and by western blot analysis.  
 
15. Cell Cycle analysis 
For cell cycle analysis of GAPDH knocked down cells, control siRNA cells, APE1-
EYFP,Apn1- EYFP expression cells, cells were transfected 36 hours prior to nocodazole 
(200 ng/mL) (Sigma) treatment to arrest cells in G2/M phase. The collection of the 
sample starts after nocodazole treatment by the addition of trypsin (Wisent). Collected 
cells were then washed with PBS/1% EDTA to prevent clumping of the cells. Cells are 
stored in 75% Ethanol in PBS in FACs tubes at -20°C until the FACs analysis was done. 
During cell collection for cell cycle analysis a fraction of the collected cells was kept at -
80°C for western blot analysis. Samples were collected as follows: 
-Sample 0: cells not treated with nocodazole after 36 hours of transfection. 
-Sample 12 hours, 24 hours and 36 hours: cells collected after 12, 24 and 36 hours of 
nocodazole treatment. 
Before flow cytometry analysis, cell suspensions were centrifuged and washed with PBS 
to remove ethanol. Then they were resuspended in 500 μL of PBS with 0.05 μg/μL of 
propidium iodide to stain the DNA. The collected samples are subject to FACs analysis 
on the FACScan machine (Becton Dickinson) according the standard protocols. Data 
were analyzed using Cell Quest Pro allias software.  
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16. Indirect immunofluorescence 
For monitoring APE1 localization in GAPDH knock down HCT116, 750,000 cells were 
plated. 24 hours cell were transfected with the corresponding siRNA as section 10. 24 
hours after transfection, 125,000 cells were transferred to a sterilized cover slip in a 6-
well plate. Cells were left for 48 hours to allow them to adhere to the glass surface of the 
coverslip.  
Fixation and permeabilization: remove the media from the 6-well plates and wash the 
cells with 2mL of PBS. Cells were then incubated with 1 mL of 3% Paraform aldehyde 
(PFA) (Sigma) for 20 minutes. The PFA was removed and the cells are incubated with     
2 mL of permeabilization buffer (PBS, 0.5% NP-40, 1mM Sodium azide) for 30 minutes. 
The cells are then washed with washing buffer (PBS, 0.1% NP-40, 1mM Sodium azide) 
and the blocking solution (10% FBS) for 1 hour. 
Primary antibody: The primary antibody mouse anti-APE1 (cedarlane) 1:150 dilution 
was prepared in blocking solution. The coverslips holding the cells were then removed 
from the 6-well plate and 50 μL of primary antibody was added onto the cells and 
covered with a parafilm of the size of the coverslip. The primary antibody was left to 
incubate for 3 hours at room temperature.  
The cells were then washed with washing buffer for 3 times/15 minutes each. 
56 
 Secondary antibody: The secondary antibody, goat anti-mouse coupled to AlexaFluor 
(AlexaFluor 488, Invitrogen) was used at 1:500 dilution and was added to the cells as 
described for the primary antibody.  
The cells were then washed with washing buffer for 3 times/15 minutes each. Then the 
cells were washed twice with PBS.  
Mounting: the coverslips were rinsed with milliQ water, and dried gently using a paper 
towel. 15 μL of the mounting media (Vector laboratories, Inc. Burlingame, CA) 
containing DAPI was put on the slide and the coverslip was placed on top of it, with the 
cells facing down. The slides were then ready for microscopy. The slides were 
subsequently examined under a Leica, DMRE, Wetzlar fluorescence microscope 
supplemented with a camera. Exposure times varied from 300-400 ms. Slides were stored 
in the dark.
Chapter 3: Results 
1. GAPDH knockdown in HCT116 causes G1 
arrest 
To determine whether GAPDH is required for APE1-dependent DNA repair function, 
we used siRNA knockdown to reduce its expression in HCT116 cells. As a negative 
control we used a scrambled control siRNA that has no significant homology to any 
known gene sequence. The knockdown efficiency was verified by western blot using 
anti-GAPDH antibody (Figure 11). 
 
                   
 Figure 11. Verification of GAPDH knockdown in HCT116. HCT116 cells were 
incubated with 75 nM of either control siRNA or GAPDH siRNA, 36 hrs later total cell 
extracts were analyzed for GAPDH by western blot.  
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Since GAPDH knockdown HCT116 cells showed proliferative defects when challenged 
with DNA damaging agents [156], we sought to determine whether they also show cell 
cycle defects in the absence of exogenous DNA damage.  
For cell cycle analysis, control siRNA and GAPDH knockdown cells were untreated and 
treated with nocodazole, 36 hours after the knockdown, to arrest cells in G2/M, then 
samples were collected after 12, 24 and 36 hours and processed for flow cytometry 
analysis. 
After 36 hours of nocodazole treatment, around 70% of the control siRNA cells 
progressed to G2/M, whereas in GAPDH knockdown cells, only 37% were in G2/M 
phase (Figure 12). One possible explanation for this result is that the arrest is caused by 
the accumulation of unrepaired AP sites, which was previously observed in these cells 
[156].  
To test this hypothesis, we expressed the major yeast AP endonuclease Apn1 in GAPDH 
knockdown cells. Unlike APE1, Apn1 does not require GAPDH for optimal activity since 
it does not contain redox sensitive cysteine residues as in the case of APE1 [84]. Apn1 
would therefore be expected to rescue the GAPDH G1 arrest only if it is caused by 
accumulation of AP sites.  
HCT116 cells were transiently co-transfected with Flag-Apn1 expressing plasmid along 
with GAPDH siRNA. Indeed, the transient expression of Apn1 in GAPDH deficient cells 
was able to release the G1 arrest (Figure 12). For instance, after 36 hours of nocodazole 
treatment, 55% of the cells progressed to G2/M compared to 37% of GAPDH knockdown 
cells not expressing Apn1 (Figure 12).  
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These results suggest that accumulated DNA damage underlies the observed cell cycle 
progression defects. It is most probably due to defective APE1 proteins in the absence of 
adequate amount of GAPDH for their activation. 
To validate the complementation effect of Apn1, we next attempted to establish stable 
HCT116 clones expressing it. The selection was done using G418 over 3 weeks. Then 
single colonies were picked and subcultured. Protein extracts of different colonies were 
subject to western blot analysis using a Flag antibody. Unfortunately, we were unable to 
detect Apn1 expression. Another attempt to create Apn1-expressing stable clones was 
done with a different construct that expresses Apn1-EYFP as shown in Figure 21 for 
APE1 variants. A fluorescent tag would make the selection process easier by allowing 
monitoring of expression using microscopy and giving the advantage of the use of cell 
sorting as another mean of selection. Similarly, we created a construct that expresses 
APN1-E158G-YFP, the AP endonuclease-deficient mutant of Apn1[188]. G418 was used 
for the selection as described in section 14 of chapter 2. The expression of the YFP-
tagged Apn1 and Apn1-E158G in these stably transfected cell lines was monitored under 
a fluorescent microscope (data not shown). The expression of both proteins was seen as 
short as 6 hours after transfection by microscopy. Unfortunately, 48 hours later the 
number of cells showing fluorescent proteins start to decrease from the cell culture. Four 
days later, no cells were showing any expression of the EYFP-tagged proteins as 
compared to the empty vector that showed a very good expression of the EYFP. One 
possible explanation is that, as a foreign protein, Apn1 might need some posttranslational 
modification by yeast proteins (e.g. chaperones, etc…) that are not present in human cells 
for its proper folding. 
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Figure 12. GAPDH knock down causes a G1 arrest. GAPDH knockdown cells transfected with 
Apn1 showed normal cell cycle progression, a result obtained in 3 independent experiments.  
 
Interestingly, we observed that cells start to die few hours after transfection with Apn1 
plasmid, which could explain the gradual decrease in the number of cells expressing Apn1 and 
hence the failure in establishing stable clones. 
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2. siRNA mediated GAPDH silencing triggers 
the formation of APE1 aggregates 
Upon oxidative stress, some BER enzymes including OGG1 and APE1 localize to 
nuclear speckles, structures that are present between chromatin domains enriched with 
RNA processing and transcription proteins [187]. To verify whether GAPDH cellular 
level affects APE1 localization, we carried out an indirect-immunofluorescence 
experiment using APE1 antibody in GAPDH knockdown and control siRNA cells. While 
normal nuclear distribution was observed in control siRNA cells, in GAPDH knockdown 
cells we detected foci in the nucleus of the majority of the cellular population (Figure 
13). The nature of the detected structures needs further investigations; we speculate that 
they could be stalled DNA repair foci of inactive APE1 on DNA lesions or it could just 
be an aggregation due to misfolding of the oxidized proteins in the absence of enough 
GAPDH to reduce them. 
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Figure 13. APE1 nuclear aggregates in GAPDH knockdown cells. HCT116 cells 
were transfected with GAPDH siRNA or Control siRNA, 48 hours later cells were fixed 
and permeabilized for indirect-immunofluorescence microscopy. DAPI was used for DNA 
staining. 
 
3. Identification of the cysteine residue(s) in 
APE1 that are reduced by GAPDH  
We next sought to identify the cysteine residue(s) that are involved in the reduction of 
APE1 by GAPDH. The conservation of cysteine residues between APE1 and bacterial 
Exo III is limited to two residues, Cys208 and Cys310. On the other hand, all seven of the 
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cysteines present in human APE1 are conserved in other vertebrates except for Cys138 
and Cys65 [189]. However, none of these cysteines are considered part of the catalytic 
active site of the protein. Nonetheless, oxidation and reduction of these cysteines could 
still affect the catalytic activity by inducing a conformational change in the protein, 
affecting the active site. We mutated each of the seven cysteine to alanine in an 
expression vector that includes a His tag. Mutants created include: C65A, C93A, C99A, 
C138A, C208A, C296A and C310A (Figure 14). As controls, active site mutants, 
D210A, D308A and H309A were also created. Table II summarizes the current 
knowledge of the function of these mutants and Figures 15 and 16 show the position of 
cysteine residues in the APE1 protein. 
The created cysteine mutants are going to be the subject of an in vitro redox state 
characterization as well as of a complementation experiments in HCT116 cells to identify 
the residue(s) that are affected by GAPDH reduction of APE1.   
 
Figure 14. His-APE1 cloning sites in pET-14b. APE1 and its variants were cloned between 
Xho I and BamH 1 restriction sites, expressed as His-fusion proteins under the control of T7 
promoter. pET-14b has an ampicillin resistance gene. 
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Figure 15. APE1 Linear map showing Cysteine residues and the three active site residues 
mutated to Alanine. DNA repair and redox domains are indicated [124, 155]. 
 
 
                                   
Figure 16. Positions of Cysteine residues within APE1 positioned relative to the active 
site H309 [190]. 
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 APE1 variants Consequence(s) on APE1 function 
C65A  Loss of redox function  
C93A  Loss of redox function  
C99A  Loss of affinity to DNA at high [Mg2+] 
C138A  ?  
C208A  ?  
C296A  ?  
C310A  DNA repair Efficient  
H309A  Low affinity to DNA, No incision activity  
D210A  Low incision activity  
D308A  Less binding to DNA, Less incision 
 Table II. Effects of the created mutations on APE1 redox and DNA repair functions [105, 
125, 138, 191, 192].                                       
 
We next purified the His-tagged APE1, native (Figure 17A) and cysteines mutants 
(Figure 17B) .Bacterial protein extract were loaded onto a column with cobalt-coupled 
beads, where the imidazole ring of the Histidine residues of adjacent polyhistidine-tag 
binds with high affinity to the cobalt ion. After several steps of washing to eliminate 
impurities, His-APE1 was eluted by competition with a buffer containing a high 
concentration of imidazole. Eluted proteins were collected by fractions of 500 μL/fraction 
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(figure 17A). Next, we purified GST-tagged GAPDH (Figure 18) proteins from E.coli 
using glutathione sepharose affinity purification.  
      
 
 
 
 
 
 
Figure 17. Purification of His-APE1, native and cysteine mutants. A.Wildtype His-APE1 
purified protein elution fractions. Elution fractions were loaded in same order of elution on a 
SDS-PAGE (12%) under reducing conditions (6.25% β-mercaptoethanol). The gel was stained 
with Coomasie blue. His-APE1 was detected at the expected size (37kDa). The observed low 
molecular weight fragments were eliminated after the dialysis step.  B. Purification of APE1 
cysteine mutants. One elution fraction of each purified protein was loaded on a SDS-PAGE 
(10%) under reducing conditions. The gel was stained with Coomasie blue.             
 A 
 
B 
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Figure 18. GST-GAPDH purification. Extract: total bacterial protein extract. FT: flow through. 
W: washing buffer fraction.E1E5: elution fractions.  
 
4. In vitro reduction of APE1 by GAPDH  
After creating and purifying APE1 cysteine mutants, we sought to choose an adequate 
assay to identify candidate cysteine (s) involved in the reduction of APE1 by GAPDH. 
We decided to use silver staining assay which is used to detect proteins in a gel. This 
protein detection technique is about 50 times more sensitive than the conventional 
Coomasie Brilliant blue staining in detecting trace amounts of proteins in a SDS-PAGE 
[193]. 
The use of this technique to evaluate the redox state of proteins assay was validated 
before [156] as an enhanced protein staining was observed under reducing conditions 
compared to non-reducing conditions.   
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Under reducing gel migration conditions (i.e. addition of 2-mercaptoethanol in the 
protein loading buffer), we observed that purified wild-type APE1 is more intensely 
stained with silver nitrate compared to non-reducing conditions (Figure 19, lanes 1 and 
2). Similarly, when His-APE1 was incubated for 10 min with GAPDH under non-
reducing conditions, an enhanced staining of APE1 was noticed (Figure 19, lane 4). This 
indicates that GAPDH is reducing APE1.  
The incubation of APE1 with both GAPDH and 2-mercaptoethanol had no additional 
effect on the staining of APE1 by silver nitrate, indicating that GAPDH is able to fully 
reduce APE1 (data not shown). 
It is noteworthy that when APE1 migrates in the absence of a reducing agent (Figure 19, 
Lane 2), it cannot be detected by silver stain. This triggered us to monitor APE1 redox 
state by other means than the silver staining, that is by western blotting [156].                                                 
APE1 was incubated with and without 2-mercaptoethanol (Figure 20, lanes 1 and 2) or 
with GAPDH for different time periods (Figure 20, lane 3, 4 and 5). Under non-reducing 
conditions and in the absence of GAPDH, APE1 forms high molecular weight species 
(~175 kDa) that most probably correspond to oxidized aggregated proteins (Figure 20, 
lane 1) that were not detected by silver staining (Figure 19, lane 2). When GAPDH was 
added to the reaction, APE1 can be detected at its predicted molecular weight of 37 kDa 
with the anti-His antibody, similarly to what was observed when APE1 was loaded under 
reducing conditions (Figure 20, lane 2).  
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Figure 19. In vitro reduction of His-APE1 by GST-GAPDH.  Purified His-APE1 and GST-
GAPDH were incubated for 10 min at 37°C; the reaction was stopped on ice and by the addition 
of the protein loading buffer. Samples were run on a SDS-PAGE (12%) and the gel was stained 
with silver nitrate as described in chapter 2, section 3. The lower band in lanes 4 and 5 is an 
impurity (GST as seen by western blot using anti-GST).  
 
We next attempted to test the purified APE1 cysteine mutants under the same assay 
conditions. We anticipate that GAPDH might cause a conformational change in APE1 
structure by reducing an intramolecular disulfide bridge(s) between cysteine residues that 
forms as a result of oxidation of the protein. Therefore, APE1 cysteine mutants will be 
assayed for their redox state to identify which mutant(s) will have enhanced silver 
staining. This mutant is expected to be more reduced, independently of GAPDH 
compared to the native APE1, as a Cys to Ala mutation will simulate the reduced state of 
the substituted cysteine since Alanine cannot be engaged in disulfide bridge formation 
upon oxidation. This experiment is still in progress.    
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Figure 20. GAPDH reduction of APE1 is a fast reaction. His-APE1 and GST-GAPDH were 
incubated for at 37°C for different periods of time (up till 45 min, not shown). Samples were 
run on a SDS-PAGE (12%) followed by western blot (anti-his antibody). The reduced APE1 is 
seen at 37 kDa. In lane 2, 2-mercaptoethanol was the reducing agent used. MW: molecular 
weight. 
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5. Cloning of APE1 variants in pEYFP-N1 
vector for expression in mammalian cells 
In addition to the in vitro characterization of APE1 cysteine mutants redox state in 
relation to GAPDH, we sought to express theses variants in mammalian cells. Our model 
predicts that APE1 cysteine mutant that cannot be oxidized will rescue the cell cycle 
defects seen in GAPDH deficient cells, as this mutant APE1 will remain active 
independent of GAPDH. For expression in mammalian cells, APE1 variant were cloned 
in pEYFP-N1 (figure 21). 
 
Figure 21. pAPE1-EYFP construct for expression in HCT116. APE1 variants were 
cloned in pEYFP-N1 vector. APE1 stop codon was removed to allow the expression of APE1-
EYFP fusion protein. In addition, a Kozak sequence (GCC ACC) was added to APE1 PCR 
primers to enhance the translation of corresponding mRNAs and hence the protein expression.  
The EYFP gene contains four amino acid substitutions which makes the emission spectrum in the 
green-yellow region. 
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6. Establishing stable clones expressing APE1 
cysteine variants 
HCT116 were transfected with APE1-EYFP expression constructs and subjected to G418 
serial selection to generate stable clones. The expression of APE1 variants in the 
established stable clones is monitored by fluorescent microscopy and by western blotting 
(in progress). All of the APE1-EYFP variants were localized in the nucleus (data now 
shown).
Chapter 4: Discussion 
The diverse functions of APE1 as a DNA repair enzyme and a redox factor render it an 
essential gene for cell survival. Studying the consequences of APE1 activation by 
GAPDH, another essential gene, is of great importance to unravel a new posttranslational 
modification affecting APE1 activity as well as the indirect involvement of GAPDH in 
maintaining the genomic stability.  
In the present study we investigated the consequences of GAPDH knockdown on the cell 
cycle progression and we reported that cells in which GAPDH is knocked-down arrest in 
G1 phase. APE1 subcellular localization study showed that APE1 forms foci-like 
structures in the nucleus of cells knocked down for GAPDH.   
Since GAPDH activation of APE1 is achieved by reduction, we sought to search for the 
cysteine residue(s) that are possibly targeted by GAPDH. APE1 cysteine mutants were 
created by site-directed mutagenesis and purified using affinity chromatography. In vitro 
attempts to identify the redox-sensitive cysteine (s) target(s) of GAPDH reduction did not 
succeed so far due to the quality of the purified proteins. A construct for expression of 
EYFP-tagged APE1 variants, including cysteine and active site mutants, in mammalian 
cells was successfully established and the expression was seen under the microscope.  
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1. GAPDH deficiency causes G1 arrest 
GAPDH is an essential gene, hence a knockdown instead of a knockout approach was 
used to evaluate GAPDH role in activating APE1 in mammalian cells. siRNA 
knockdown of GAPDH caused a defect in cell cycle progression, which was not 
surprising since a decrease in cell proliferation was also seen in GAPDH knockdown 
cells (Ramotar Lab, unpublished data). Moreover, GAPDH deficiency caused an increase 
in the formation of spontaneous AP sites and showed a decrease in the AP endonuclease 
activity of the cells [156]. These data suggest that the delay seen in the cell cycle is most 
probably due to an accumulation of AP sites which is known to activate checkpoints, 
delaying cell cycle progression to allow repair [194]. Checkpoints signalling pathways 
activate damage-specific DNA repair mechanisms, in this case the BER, before the 
transition from G1 to S phase and prior to DNA synthesis [195], as BER pathway is 
mostly active in G1 phase where oxidized bases and strand breaks are repaired [194].   
The observed G1 arrest of GAPDH depleted cells might be occurring via the classical 
activation of p53 by phosphorylation on Ser-15, which was reported by another group 
that also showed that siRNA-mediated GAPDH knockdown accumulate in G1 phase 
[196]. It would be also interesting to examine checkpoints activation in knockdown cells 
by monitoring Chk1 and Chk2 phosphorylation state by western blot analysis.   
 
 
 
75 
2. Use of Apn1 for complementation assays 
Given that APE1 is the major human AP endonuclease responsible for processing AP 
sites, the accumulation of oxidized inactive species of this protein in GAPDH knockdown 
cells explains the deficiency in AP endonuclease activity observed in these cells [156], 
which might also validate the observed cell cycle defects. Complementation strategy was 
used to verify that the lack of APE1 activity is the reason behind the G1 arrest. 
Overexpression of wild type APE1 in GAPDH depleted cells can be confusing since the 
ratio of the endogenous to the introduced APE1 in addition to the redox state of the total 
APE1 population were a concern. Consequently, the expression of the yeast Apn1 that is 
not redox sensitive was used to verify the implication of APE1 activity in the defective 
cell cycle, as this enzyme shares many functional features with APE1, most importantly 
the repair of AP sites. A direct measurement of AP sites frequency in GAPDH 
knockdown cells transfected with or without Apn1 plasmid can be done to further verify 
Apn1 rescuing effects. In fact, complementation experiments in which Apn1 was 
expressed in mammalian cells and compensated for a deficiency in APE1 activity were 
reported [121].  
 
3. Apn1 expression in HCT116 cells is lethal 
We noticed that stable and transient transfection of HCT116 cells with Flag- and EYFP- 
tagged Apn1 was causing many cells to die about 24 hours following transfection. The 
observed cell death, that probably explains the expression problems seen in Apn1 
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transfected cells, prompted us to think that Apn1 might be toxic for the cells. Importantly, 
Apn1 expression under the constitutive CMV promoter in GAPDH knockdown cells, 
where higher AP site frequency was observed, caused even an increased lethality. In fact, 
it was shown that the overexpression of Apn1 in a cells with high frequency of  AP sites 
enhances cells sensitivity to MMS [197]. It seems that cells are better able to tolerate 
intact AP sites than the strand breaks generated by Apn1 incision. 
Hence, during cell cycle analysis, the rescuing phenotype attributed by Apn1 in GAPDH 
knockdown cells might be due to surviving untransfected cells.  
 Interestingly, the expression of the enzymatically inactive variant of Apn1, E158G, did 
not increase cell death in GAPDH knockdown cells as compared to wild type Apn1. 
Therefore, we plan to design a survival assay (e.g. the clonogenic assay) where we 
monitor the effects of Apn1 and its inactive variant on the survival of GAPDH 
knockdown cells.    
 
4. Apn1 stable clones 
Considering the difficulties faced in transiently expressing Apn1 in HCT116, we tried to 
establish stable HCT116 cell lines expressing Flag-Apn1 similarly to what was done 
before [121]. After three weeks of selection with G418 and after isolating and growing 20 
separate single colonies, western blot analysis with anti-Flag antibody failed to show any 
expression of Apn1. Another attempt to detect Apn1 expression using a serum containing 
Apn1 antibody prepared in the laboratory was unsuccessful. 
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Surprisingly, Fung and Demple (2005) [121] successfully established stable clones 
expressing Flag-Apn1 in HCT116 and that was proved by western blot analysis. 
Although we were using the same protocols and the same cell line, we were unable to 
reproduce their work.  
Establishing stable clones using Apn1-EYFP and its variant Apn1- E158G-EYFP 
constructs was not very successful either. We detected a low level of expression 
corresponding to a low number of cells showing fluorescent proteins. Four days after 
starting the treatment with G418, and a total of six days after the transfection, almost 
none of the cells expressed the fluorescent Apn1 and its variant, most probably due to cell 
death. The pEYFP-N1 vector that we are using has an origin of replication that is induced 
by T antigen, hence expressing Apn1 in HEK 293T cells that have SV40 T antigen might 
be an alternative.  
It is noteworthy that using the same construct and the same cell line, the expression of 
APE1- EYFP variants was successful and stable clones were established. As a foreign 
protein, Apn1 proteins might be unstable in mammalian cells context, which could lead 
to their degradation due to the absence of potentially needed yeast proteins for its proper 
folding. Moreover, the presence of a tag might also be interfering with the protein folding 
and stability. RT-PCR of RNA extracts from Apn1-transfected cells will provide an 
evidence of whether the expression problem is at the protein level or at the transcriptional 
level.    
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5. APE1 foci-like structure could be aggregates 
of oxidized species                   
Upon oxidative stress, as a DNA repair enzyme and a transcription regulator, APE1 
translocates to the nucleus [104]. In fact it is considered mainly a nuclear protein, 
although many reports showed its cytoplasmic localization that was correlated to 
tumoregenesis [198]. It was shown to localize to the endoplasmic reticulum (ER) where it 
forms a complex with other proteins and might get cleaved at its Lys 31 giving rise to 
NΔ33APE1 form that was shown to localize to the mitochondria [185, 186].  
It was not surprising that APE1 was localized to the nucleus in our indirect- 
immunofluorescence experiments, but what was striking is the foci-like structures seen 
only in GAPDH knockdown cells and not in the control cells. They could be either 
nuclear foci composed of recruited and inactive APE1 that retains the ability to be 
recruited to DNA damage sites or they simply represent aggregates of oxidized forms of 
APE1 in the absence of enough GAPDH to reduce the proteins. 
 A key experiment where we test if the observed APE1 structures co-localizes with 
XRCC1, a BER enzyme that usually co-localize with APE1 on DNA lesions [199], might 
favor the nuclear foci hypothesis. Additionally, the expression of Apn1 in these cells is 
expected to abolish the formation of these foci by competing with the inactive APE1 for 
recruitment and binding to DNA lesions. Alternatively, if what we observed was just 
protein aggregates, treatment of GAPDH knocked down cells with reducing agents such 
as the antioxidant N-acetyl cysteine (NAC) should abolish APE1 nuclear “aggregates” by 
conferring a reduced cellular environment that can compensate for the lack of GAPDH.  
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Furthermore, monitoring APE1 subcellular localization in each phase of the cell cycle of 
GAPDH knockdown cells will provide us with the status of APE1 in G1 where the cells 
are arresting: are these nuclear foci present mainly in G1? If these foci are present evenly 
in all cell cycle phases, they are most probably a result of aggregation of oxidized 
proteins.  
 
6. Purified cysteine mutants aggregate 
There are many possible reasons behind the problems encountered with the purified 
APE1 mutants. First, the purified proteins were aggregating, as we saw the non-
homogeneity of the protein-containing solution by the naked eye. Attempts to change 
storage conditions (buffer, temperature) and to remove the observed white aggregates 
from the solution by high speed centrifugation, failed to resolve the quantification 
problem. The addition of DTT might have solved the problem but since we are interested 
in the redox state of these proteins, the addition of a strong reducing agent will interfere 
with our assays.  
Second, purified proteins were extracted from 1L of bacterial culture, which yielded 
enormous amounts of proteins as visualized by SDS-PAGE. The high concentration of 
purified proteins can cause aggregation. We tried to dilute the protein suspensions but the 
aggregation problem was not solved. Starting with a smaller bacterial culture could be a 
better idea than diluting what is already aggregated.  
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Oxidized proteins tend to aggregate in solution due to many reasons but mainly because 
of the formation of inter-and intra-molecular disulfide bridges. However, it is surprising 
that cysteine mutants would aggregate taking into consideration that a lack in a cysteine 
residue presumably will result in less disulfide bridge formation, hence less aggregation.  
Other groups have purified these variant with no mention of such problems [191]. 
However, to make cysteine mutants they used Cys to Ser mutation and they also used 
DTT in their purification buffers. 
 
7.  Expression of APE1 mutants in AP 
endonuclease deficient bacteria 
To test the functional state of APE1 cysteine mutants in vivo, we tried to express them in 
a bacterial strain, BW528 [Δ(xth-pnc), nfo1::kan], lacking both Endo IV and Exo III AP 
endonucleases and look for complementation when challenged with DNA damaging 
drugs. Interestingly, the expression of wild type APE1 as well as its cysteine mutants in 
this strain was lethal compared to the empty vector. Lethality was more striking in wild 
type APE1, C65A, C93A and C99A transformed bacteria (data not shown). Considering 
that it lacks AP endonuclease activity, this strain is expected to accumulate a high level of 
unrepaired AP sites. If they are functional, the expression of APE1 and its variants in this 
strain will possibly catalyze the incision of these abundant AP sites, leading to DNA 
fragmentation which possibly explains the lethality, an observation reported in yeast 
where the overexpression of Apn1 is lethal [197]. Another observation in this context was 
in C.elegans where the knockdown of APN-1 suppressed lethality in strain where 
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depletion of dUTP nucleotidohydrolase (DUT-1) results in an increase of mis-
incorporated uracil in the DNA, which will be removed by uracil-DNA glycosylase 
(UNG-1) leaving a lot of AP sites behind [95]. It is noteworthy that the transformation of 
BL21 E.coli strain that does not lack Exo III and Endo IV was successful.  
 
8. Conclusion and future work 
GAPDH was shown once again to be more than just a glycolytic enzyme. We revealed a 
novel role for this enzyme in DNA repair by maintaining APE1 activity. Depletion in 
GAPDH caused an increase in the mutagenic AP site lesions, arrested the cells in G1 
phase, halted cell proliferation and caused APE1 to form nuclear foci-like structures that 
needs to be studied further. Therefore, by activating APE1, GAPDH is helping in 
maintaining the genomic integrity of the cells and promoting their survival under normal 
conditions, during oxidative stress and when challenged with DNA damaging agents. 
Moreover, GAPDH reduction of APE1 emphasizes the importance of APE1 
posttranslational modifications in defining its functional pattern as a multifunctional 
protein. But more questions related to APE1-GAPDH interaction need to be addressed: 
which APE1 cysteine residue(s) is the target of reduction by GAPDH? Does this 
reduction reaction trigger a conformational change in APE1 structure rendering it active? 
In addition to its DNA repair function, does this interaction affect the redox function of 
APE1? 
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8.1 Study the AP endonuclease activity of APE1 
variants  
Although there are many reports where the activity of these variants was tested (see table 
I of chapter 3), some of these reports used Cys to Ser instead of Cys to Ala substitution 
and used different conditions under which the assays were performed. Therefore, in the 
process of identifying the cysteine residue(s) of APE1 that are reduced by GAPDH, it is 
of major importance to study the AP endonuclease activity of these mutants after 
oxidizing them with H2O2 using the AP endonuclease assay. This assay allows the 
detection of AP endonuclease activity using a 42 mer radiolabled oligonucleotide  
containing a centered AP site as described previously [96]. This substrate is then 
incubated with the enzyme that, when active, will cleave the AP site, leading to the 
formation of a 20 mer radiolabled fragment that migrates faster than the intact substrate 
on a 10% polyacrylamide/7 M urea gels. The mutant(s) that retain their AP endonuclease 
activity will be expected to play a complementing role in AP endonuclease deficient 
yeast cells for instance and in GAPDH deficient cells. This mutant will be a possible 
candidate of GAPDH reduction. On the other hand, the mutant(s) lacking the AP 
endonuclease activity might be crucial for APE1 catalytic activity and will need further 
investigation since no cysteine residue has been reported to participate in APE1 catalytic 
reaction. As controls, we are going to use APE1 active site mutants, H309A, D210A and 
D308 in addition to the wild type APE1 and Apn1. We are mostly interested in the 
C310A variant since it was shown that the oxidation of this protein by H2O2 did not affect 
its AP endonuclease activity [155]. 
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8.2 Expression of APE1 cysteine mutants in GAPDH 
knockdown cells  
The HCT116 stable clones expressing wild type APE1 and its cysteine mutants will be 
knocked down for GAPDH and will be assayed for cell cycle analysis, subcellular 
localization studies, and measurement of AP sites frequency and AP endonuclease 
activity of total cell extracts. We expect that at least one cysteine mutant will be active in 
the cells similarly to a wild type but that is not susceptible for redox inactivation. This 
variant is expected to release cells from the G1 arrest seen in GAPDH depleted cells. In 
addition, whether APE1 foci-like structures seen in GAPDH knocked down cells are 
protein aggregates or nuclear foci on DNA lesions, this variant is not expected to form 
such structures as we expect it to be reduced and active independent of GAPDH. We also 
anticipate that GAPDH knockdown cell expressing this variant will have less 
spontaneous AP sites and an enhanced AP endonuclease activity. 
 
8.3 Expression of APE1 cysteine mutants in AP 
endonuclease deficient yeast strain 
The AP endonuclease deficient S. cerevisiae YW778 strain in which APN1 and APN2 
were deleted will be used as a host for APE1 cysteine mutants complementation studies. 
To clone these mutants in a yeast expression vector we are planning to use gap-repair 
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cloning. Next, the transformed YW778 strain will be subjected to survival assays using 
many DNA damaging agents such as MMS, H2O2 and bleomycin. UVC will be used as a 
negative control. 
 
8.4 GAPDH-induced APE1 Conformational change 
Most posttranslational modifications affect the activity of their targets proteins by acting 
on their conformation, such as hiding or exposing the active site, an interaction domain, a 
localization signal, etc… In proteins, thiol groups (-SH) present on cysteine residues are 
susceptible to oxidation that will engage two cysteines to form a disulfide bridge (R-S-S-
R), a phenomenon known to be reversible by the addition of an adequate reducing agent. 
These intra-molecular changes are expected to cause conformational changes of the 
protein; especially if thiol groups are abundant as in the case of APE1 that has seven 
cysteine residues. We believe that this is the case of APE1 reduction by GAPDH. To test 
this hypothesis, we plan to use circular dichroism (CD) analysis to study purified 
APE1structural changes after its interaction with GAPDH, in addition to the proper 
controls, in the far UV range.  
 
8.5 Study the effect of GAPDH on APE1 redox function  
So far we know that GAPDH reduction of oxidized APE1 activates its DNA repair 
function [156], but no characterization of its redox function in relation to this reduction 
has been done yet. Thioredoxin was shown to reduce and enhance APE1 redox function 
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which in turn enhances the AP-1 DNA binding and p53 activation [153, 154]. To 
examine whether GAPDH is involved in the regulation of APE1 redox function, activity 
of the major transcription factors regulated by APE1 (AP-1, p53, Jun, Fos…) in GAPDH 
knockdown cells should be tested. For instance, to check AP-1 activity we plan to check 
the activity of the human collagenase I promoter in GAPDH knockdown cells, which 
contains an AP-1-binding site, as described previously[153]. It remains possible that 
thioredoxin and GAPDH may perform distinct redox functions on oxidized APE1. 
However, since Apn1 does not have a redox function, the effect of its expression in 
GAPDH knockdown cells is of great importance in differentiating between the redox and 
repair functions of APE1 that could be regulated by GAPDH.    
 
9. Perspectives 
Unrepaired AP sites lead to an increase in cytotoxicity, cancer or apoptosis [12]. As the 
major DNA repair enzyme that processes AP sites, APE1 plays an essential role in 
maintaining genomic integrity and promoting cell survival, hence the importance of the 
regulation of its activities in normal as well as in cancer cells. In our laboratory, we 
showed that GAPDH deficiency sensitizes the cells to bleomycin which induces DNA 
strand breaks with blocked 3’-termini processed by APE1. Consequently targeting its 
DNA repair function through GAPDH could be a novel mechanism for APE1 
involvement in chemotherapeutic treatments. By preventing structural inactivation of 
APE1, we believe that GAPDH is acting to maintain the genetic stability which might 
explain GAPDH involvement in the pathology of many oxidative stress related 
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neurodegenerative diseases where an accumulation of mutations leading to apoptotic cell 
death was shown [200].
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